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SUMMARY
About one in eight women in the United States will develop breast cancer over
the course of her lifetime. To make matters worse, patient-to-patient variability in
disease progression continues to complicate clinical decisions in diagnosis and treat-
ment for breast cancer patients. Early detection of tumors is a key factor influencing
patient survival, and advancements in diagnostic and imaging techniques has allowed
clinicians to spot smaller sized lesions. There has also been an increase in premature
treatments of non-malignant lesions because there is no clear way to predict whether
these lesions will become invasive over time. Patient variability due to genetic poly-
morphisms has been investigated, but studies on variability at the level of cellular
activity have been extremely limited. An individuals biochemical milieu of cytokines,
growth factors, and other stimuli contain a myriad of cues that pre-condition cells
and induce patient variability in response to tumor progression or treatment.
Circulating white blood cells called monocytes respond to these cues and enter
tissues to differentiate into monocyte-derived macrophages (MDMs) and osteoclasts
that produce cysteine cathepsins, powerful extracellular matrix proteases. Cathep-
sins have been mechanistically linked to accelerated tumor growth and metastasis.
This study aims to elucidate the variability in disease progression among patients by
examining the variability of protease production from tissue-remodeling macrophages
and osteoclasts. Since most extracellular cues initiate multiple signaling cascades that
are interconnected and dynamic, this current study uses a systems biology approach
known as cue-signal-response (CSR) paradigm to capture this complexity compre-
hensively.
xiii
The novel and significant finding of this study is that we have identified donor-
to-donor variability in disease modifying cysteine cathepsin activities in macrophages
and osteoclasts. This is the first study that has explicitly and extensively investigated
inter-donor variability in cellular proteolytic activity and predicted the donor-specific
cathepsin activity with greater than 90% predictability. This study applied this novel
finding to the context of tumor invasion and showed that variability in tumor as-
sociated macrophage cathepsin activity and their inhibitor cystatin C level mediates
variability in cancer cell invasion. Furthermore, by inhibiting JNK activation of c-Jun,
a kinase that has been linked to increase in cathepsin activity, and those individu-
als whose macrophages had the highest cathepsin activity and the greatest invasive
potential saw the greatest reduction in these outcomes. Monocytes from these indi-
viduals had low level of JNK activation.
These findings help to provide a minimally invasive way to identify individuals
with particularly high remodeling capabilities. This could be used to give insight
into the risk for tumor invasion and develop a personalized therapeutic regime to




About one in eight women in the United States will develop breast cancer over the
course of her life time.[142] However, patient-to-patient variability in disease pro-
gression continues to complicate clinical decisions in diagnosis and treatment for
patients.[179, 152, 27, 40, 153, 180, 205] Although advancement in diagnostic and
imaging techniques has led to an increase in early detection of breast cancer, this
increase is also accompanied by a downside of premature treatment of non-malignant
lesions, because there is no clear way to predict whether these lesions will become
invasive over time. Patient variability due to genetic polymorphisms has been investi-
gated [71, 61], but studies on variability at the cellular proteolytic activity level have
been extremely limited.[47] An individuals biochemical milieu of cytokines, growth
factors, and other stimuli contain a myriad of cues that pre-condition cells and induce
patient variability in response to disease progression or treatment. The focus of this
work is on investigating this patient variability at the cellular activity level and eluci-
dating the underlying mechanism for the variability in order to develop personalized
medicine strategies for tissue remodeling diseases such as cancer and cardiovascular
diseases.
1.1 Interpatient variability in breast cancer
A recent study showed that the incidence of breast cancer overdiagnosis may be as
high as 30%.[11] Because currently, there is no good method to predict invasive po-
tential of non-malignant lesions, some women choose to undergo radical mastectomy
to prevent malignant progression. In fact, the lack of ways to predict patient-specific
disease potential and rate of progression is not confined to breast cancer, but extends
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to other serious and prevalent illnesses including other cancers and cardiovascular
diseases.
Advances in genomic analysis have lead to discovery of many genetic markers that
predispose a person to certain diseases with high risk factors, such as the BRCA1
and BRCA2 gene mutation for breast and ovarian cancer. Although 70% percent of
women with these mutations do develop cancer, 30% do not. Various environmental
and other molecular modifiers affect risk predictions.[136] A number of studies that
identified vast intratumoral heterogeneity within one patient further multiplies the
complexity of determining prognosis and treatment regimens. [161, 53, 144, 8] It
is clear that a one-size-fits-all approach of diagnosis and treatment is not the most
effective or cost-efficient way to treat and eliminate multifactorial diseases. There is
clearly a need for a personalized approach.
1.2 A need for personalized medicine
Physicians have explored the idea of personalized medicine by taking a trial-and-
error approach to find best course of treatments for individual patients.[41] In more
systematic ways, n=1 or single subject clinical trials have been conducted since the
since 1986.[63, 64, 98, 79] In these studies, each patient was his or her own con-
trol and the outcomes of varying treatment strategies were compared to the control
group. Although these approaches showed efficacy, it was time-consuming and pa-
tients underwent various trials before finding the best treatment. The ultimate goal
of personalized medicine is to avoid this trial-and-error period and to be able to pre-
dict disease progression, optimized treatment regimen, and the outcomes a priori for
each patient. In the field of pharmacology, improved understanding in biochemistry,
molecular biology, and pharmacodynamics combined with advancement of compu-
tational science has allowed effective rational drug design. Although the laws that
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govern human body are complex, new readily available personalized genomic and pro-
teomic information as well as computational and experimental tools to process and
integrate a large quantify of data efficiently, will allow us to revisit the idea of n=1
methodologies to treat patients.
1.3 Roadmap to personalized medicine: considering possi-
bility versus reality
As we discussed briefly earlier, genetic predisposition is just that, a genetic tendency
or possibility to develop certain diseases. Since Francis Crick described the idea of
the central dogma of molecular biology where genetic information flows from DNA
to RNA to protein [29], scientists have found a number of ways that provided excep-
tions to the rule from epigenetic changes to regulations at the protein level. When
determining a persons chance of developing an invasive breast cancer from the ini-
tial overgrowth, what needs to be considered is not only their genetic risks but also
cellular effectors namely proteases that execute the pathogenesis and disease progres-
sion. Unlike genetic variability among individuals, studies on variability in cellular
proteolytic activities has been extremely limited.[47]
Cysteine cathepsin proteases are potent collagenases and elastases whose expres-
sion and activities are tightly regulated at multiple points along the central dogma.
Of particular interest to this current study occurs after translation. Like many other
protease families, cathepsins are synthesized as inactive precursors (procathepsins)
and to be active, cleavage of a propeptide occurs by other proteases or through au-
tocatalytic mechanisms.[23, 129, 132, 196] Once active, cathepsin proteolytic activity
is regulated by environmental factors such as temperature, pH, and oxidative po-
tential. Cathepsins are optimally active at acidic pH, and prefer reducing environ-
ments for the SH group of the active site cysteine to participate in the nucleophilic
attack that cleaves peptide bonds.[149, 33] Finally, the cystatins are a family of cys-
teine cathepsin inhibitors that regulate and inhibit intra- and extracellular cathepsin
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activity.[128, 190, 78, 192, 194] Taken together, in vivo, cathepsins exist as a system
of relatively short-lived enzymes working simultaneously on multiple substrates, both
intra- and extra-cellularly.[118] We have shown that there are appreciable patient-to-
patient variability in the amount of active cysteine cathepsin protease in monocyte-
derived macrophages and osteoclasts[155] and in cystatin C level of macrophages. As
it will be discuss further, cysteine cathepsins play central mechanistic roles in cancer
and cardiovascular diseases. These findings emphasize the need to investigate patient
variability at the level of active proteases for personalized diagnosis and treatments.
1.4 Macrophages, osteoclasts and cathepsins in cancer
Monocytes are circulating white blood cells that respond to milieu of cytokines,
growth factors, and other stimuli, and enter tissues to differentiate into monocyte-
derived macrophages (MDMs) and osteoclasts. They actively participate in tissue
remodeling by producing cysteine cathepsins. Cathepsins produced by macrophages
and osteoclasts have been mechanistically linked to accelerated tumor growth and
metastasis.[56, 138, 197, 112, 167] The variability in patients cathepsin protease pro-
duction by MDMs and osteoclasts due to the varying biochemical stimuli can be
employed to elucidate the variability in disease progression that involves cathepsins.
Cysteine cathepsins are included in the papain family of proteases that com-
prises 11 members denoted by letters: cathepsins B, C, F, H, K, L, V, O, S, W,
and Z (or X). In humans, cathepsins were first identified in lysosomes for their role
in protein turnover, but are now known to play functional roles in other cellular
compartments and even in the extracellular space after secretion.[16, 23, 38, 194]
Cathepsins are optimally active in slightly acidic and reducing environments. This
is one benefit for personalized medicine in that they are relegated to specific cell
types and subcellular compartments under healthy conditions, but then are turned
on in different cells and cellular subcompartments during disease, lending them to
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being useful biomarkers.[177, 163, 60] As an example, cathepsin K is the most potent
human collagenase[51] and was identified in osteoclasts, where it is key for bone re-
sorption. Cathepsin K is now known to be expressed in multiple cell types including
macrophages, fibroblasts, dendritic cells, chondrocytes, endothelial cells, smooth mus-
cle cells, and transformed epithelial cells in diseased conditions.[19, 188, 69, 20, 162]
Other cathepsins of interest for personalized medicine include L, S, and V, which
are in the same subclade as cathepsin K. They too have limited cell-specific expres-
sion under healthy conditions but get turned on in disease conditions in other cell
types.[163, 208] Along with cathepsin K, they can be secreted under disease conditions
as well and have been implicated in extracellular matrix degradation in pathological
disease progression.[42] Cathepsins K, S, and V are all strong elastases, with cathepsin
L having mild collagenase activity.[208, 42, 108]
Until recently, many studies have focused on identifying characteristics of cancer
cells themselves. However, it has become clear that tumor microenvironment, which
encompasses tumor cells, stromal cells, and recruited immune cells, which include
tumor associated macrophages (TAMs), play crucial roles in determining behavior
of cancer cells.[111, 43, 49, 28] TAMs that are differentiated from circulating mono-
cytes promote angiogenesis [102, 103, 104, 37, 165, 131], tumor growth[103], invasion,
and metastasis[109] through secretion of cytokines to coordinate tumor-promoting
immune responses[6, 175, 120, 123] as well as through secretion of tissue-remodeling
cathepsin proteases.[80, 55]
In tumor tissues, cathepsins are highly upregulated in both cancer cells and TAMs.
Although cathepsins were first discovered in lysosomes, they are now known to be
secreted by different cell types including macrophages and osteoclasts.[206, 50] In
cancer cells, there is increase in both intracellular and secreted cathepsin activity and
this increase is regulated at the transcriptional, translational, and post-translational
level. In vivo studies on breast cancer have shown that cathepsins L and K promote
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invasion [90], and cathepsin B promotes tumor growth, invasion and metastasis to
bone.[203] Recently, it was shown that loss of BRCA1 tumor-suppressor gene activates
cathepsin L-mediated degradation of 53BP1, which then allows cells to bypass cellular
check points and promotes tumor growth.[62] Cathepsins K and L are shown to be
elevated in ductal carcinoma in situ (DCIS).[4] In addition, it has been shown that
cathepsin secretion by cancer cells can be induced by interaction with extracellular
matrix (ECM) protein such as collagen I.[160]
Cathepsins secreted by infiltrating tumor-associated macrophages have also been
shown to promote cancer cell invasion[197] and to blunt effectiveness of chemother-
apy against breast cancer cells.[172] For prostate cancer, cathepsin B was shown
to promote angiogenesis and invasion[143] and cathepsin S secreted by infiltrat-
ing macrophages were associated with poorly differentiated tumors and castration-
resistant tumors.[110] For pancreatic cancer, cathepsins B and S have been shown
to promote angiogenesis and tumor formation[57] and cathepsins B and L promote
cancer cell proliferation and growth.[57, 200] Lack of cystatin C, an endogenous in-
hibitor of cysteine cathepsins, increased the number of pre-malignant lesions. On the
other hand, tumor metastasis to lung but not to liver, two of common metastatic
sites, was reduced when cystatin C was overexpressed. Taken together, specialized
role of individual cathepsins in multiple stages of tumor progression and by different
cell types provide opportunities for tailored prognosis as well as targeted therapies to
minimize undesired effects.
The role of cathepsin K, traditionally known to be secreted by osteoclasts, have
been investigated mostly in the context of metastasis to bone, which is a common
metastatic site for prostate, breast, and lung cancer. These metastatic cancer cells
have shown various osteoclast-stimulating properties. [25, 189, 181] Increase in os-
teoclast differentiation or stimulation of osteoclasts leads to increase in cathepsin K
secretion and bone resorption, which in turn releases growth factors from bone matrix
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and stimulates cancer cells.[87] Consequently, cathepsin K inhibitors have been sug-
gested for treatment of osteolytic bone metastasis[99], but no data from large-scale
clinical trial is currently available. A number of cathepsin K inhibitors have been de-
veloped to treat osteoporosis, but only one of them, odanacatib, has completed phase
III clinical trial.[18] Cathepsins have been shown to promote cancer cell migration and
invasion [92, 139, 93], potentially through cleavage of extracellular proteins[119, 72]
and cell adhesion proteins as well as intracellular degradation of matrix proteins such
as collagen.[57] Secreted cathepsins have been linked to neoplastic transformation and
intracellular cathepsins have been linked to tumor invasion.
1.5 Kinase signaling network in understanding patient-specific
cell behavior
Despite crucial roles monocyte-derived macrophages and osteoclasts have in diseases,
how monocytes interpret environmental cues, process signals, and respond are not well
understood. Intracellular signal propagation is often transient, and the traditionally
examined cell surface markers and clusters of differentiation (CD) may not reflect this
within the critical time frame and requires novel descriptors of cell state. Moreover,
because most extracellular cues initiate multiple signaling cascades that are intercon-
nected and dynamic, a system-wide approach must be taken to accurately capture this
complexity. One tool that has been used successfully to extract important biological
information by integrating unknown and measurable variables at a nexus, is the cue-
signal-response paradigm (Figure 2). The cue-signal-response paradigm integrates
multiple extracellular cues received by cells, measures changes in the induced sig-
nals, and interprets cell decisions to execute responses (Figure 2).[75, 159, 74, 134] In
particular, computational analysis of dynamic changes in kinase activation has shown
that kinases serve as integrators of stimuli from different soluble, cellular, and physical
cues, to generate specific cellular responses.[77, 201, 101, 183] Prediction of monocyte
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differentiation and resultant proteolytic activity from an individual signaling path-
way in isolation is problematic due to complex crosstalk in signaling networks, but is
substantially improved when multiple pathways are considered (Figure 2).[135, 75]
1.6 Partial least square regression (PLSR)
PLSR is based on principal component analysis (PCA), where based on principles
of eigenvectors and eigenvalues, data sets are organized into a MxN data matrix X
(Figure 2) and new variables, called principal components (PCs), are calculated that
capture most of the information contained in the data set based on covariance between
measurements. This approach de-emphasizes measurements that are noise and shows
little covariance with other measurements and highlights the measurements that co-
vary together and identifies a global pattern in the data set. For PLSR analysis,
covariance of independent variables in the X -matrix is calculated based on how well
they describe or predict the dependent variables in the Y -matrix. Variable impor-
tance in projection (VIP) scores can be calculated to identify independent variables
that highly contribute or are predictive of the dependent variable. For each inde-
pendent variable, regression coefficient is also calculated where Y = XB + E and B
is regression coefficient matrix and E is residual noise. This coefficient matrix B is
referred to as a PLSR model and can be used to predict responses for a whole new
set of independent measurements (Figure 3).[76, 3]
1.6.1 Use of PLSR in biology
Partial least square regression (PLSR) analysis have been used in biology to generate
new hypotheses that can be tested experimentally to improve our understanding of
biology.[75] One of the advantages of PLSR analysis is that it can find new unbiased
relationships within large number of measurements based on global variations and co-
variance. In systems biology, Cue-Signal-Response (CSR) paradigm refers to cellular
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Figure 1: Cathepsins in diseases A schematic showing the role of monocyte de-
rived macrophages and osteoclasts, as well as cathepsins secreted by these cells in
atherosclerosis, osteoporosis and tumor.
Figure 2: A schematic of cue-signal-response (CSR) paradigm Kinases are
signal integrators. When a cell receives some input (cue) from its environment, signals
are propagated through activation / deactivation of multiple kinases and result in
changes in cellular behavior or responses (gene apoptosis, differentiation, proliferation
etc.).
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systems where extracellular cues such as cytokines and growth factors activates intra-
cellular signaling network which leads to functional responses by cells. For example,
M-CSF (cue) binds to its receptor and the information is propagated by activation
of multiple kinases (signal) leading to transcription of genes encoding cathepsins K,
S, L, and V.[155] A PLSR model can be generated where the kinase measurements
populate an independent matrix X and cathepsin activity measurements populate a
dependent matrix Y. Cellular proteolytic activity when stimulated with IL-4 can then
be predicted based on new set of kinase signals measured. Also, kinase signals that
co-vary with responses could have biological connections that maybe known or to be
tested experimentally.
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Figure 3: PLSR data matrix X and Y data is generated using signals (X) and
responses (Y). Using PLSR analysis, regression coefficient matrix is computed and
can be used to predict responses based on new signal matrix.
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CHAPTER II
SPECIFIC AIMS AND HYPOTHESES
The central hypothesis of this work is that by interpreting the kinase signaling net-
works of differentiating monocytes, we can understand patient-specific differences in
monocyte differentiation and predict cathepsin-mediated tissue remodeling for indi-
vidual patients.
2.1 Aim 1. Predict patient-specific cathepsin activity of
monocyte-derived macrophages and osteoclasts using
multivariate analysis of phosphokinases
Hypothesis: Multivariate analysis of phosphokinase will predict patient-specific mor-
phology of differentiated macrophage and osteoclast and their cathepsin activity. Freshly
isolated peripheral blood mononuclear cells (PBMCs) from donors were differentiated
into macrophages or osteoclasts and cultured for 14 days. On days 1, 3, 6 and 9, cell
lysates were collected for Bioplex kinase analysis of 7 kinases implicated in monocyte
differentiation. Mean-centered kinase signals as well as cathepsin activity measured
with multiplex cathepsin zymography were input into data-matrices for PLSR anal-
ysis. On day 15, cell lysates and conditioned media were collected for cathepsin
zymography and western blot to characterize activity and presence of intracellular
and secreted cysteine cathepsins K, L, S and V. Cathepsin activity was quantified by
densitometry.
2.2 Aim 2: Identify mechanisms for patient variability in
cathepsin-mediated disease outcomes.
Hypothesis: Higher macrophage cathepsin activity is associated with increased sever-
ity or faster progression of diseases. Freshly isolated PBMCs were differentiated into
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macrophages and kinase signals, cathepsin activity and cystatin C level was mea-
sured. In vitro co-culture system was used to test variability in cancer cell invasion as
proxies for disease progression to test the hypothesis that patent-specific variability
in cathepsin activity results in patient-specific variability in disease progression.
The purpose of this work was to identify patient-variability in cellular proteolytic
activity as well as to elucidate the underlying mechanism and its implication on the
development and progression of tissue remodeling diseases to achieve the ultimate
goal of personalized and predictive medicine.
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CHAPTER III
DONOR SPECIFIC PROTEOLYTIC ACTIVITY OF
MONOCYTE-DERIVED MACROPHAGES AND
OSTEOCLASTS PREDICTED WITH TEMPORAL
KINASE ACTIVATION STATES DURING
DIFFERENTIATION
3.1 Introduction
Patient-to-patient variability in disease progression continues to complicate clinical
decisions of treatment regimens for both cardiovascular diseases and cancer that orig-
inates at different sites and is diagnosed at different stages of progression. Monocytes
are circulating white blood cells that participate in pathogenesis of cardiovascular
disease and cancer in response to cues from cells or the environment by leaving
the vasculature, entering the tissue, and differentiating into macrophages or osteo-
clasts. In atherosclerotic lesions, monocyte derived macrophages ingest lipids, become
foam cells, and contribute to plaque growth and extracellular matrix (ECM) degrada-
tion and remodeling.[169] In cancer, monocyte-derived tumor associated macrophages
(TAMs) contribute to almost 50% of the tumor volume and promote tumor invasion,
migration and metastasis.[56, 57] Osteoclasts are the multinucleated cells that resorb
bone by secreting high levels of cathepsin K to cleave type I collagen, the major
structural protein in bone.[171, 17] Osteoclasts have been implicated in later stages
of atherosclerotic plaque calcification and shown to be differentiated from infiltrated
monocytes.[2, 96, 133] In cancer, osteoclasts are involved in positive feedback loops
to develop osteolytic bone lesions with metastasized cancer cells.[99, 141]
14
Once differentiated from monocytes, both macrophages and osteoclasts contribute
to tissue remodeling through the production and secretion of cysteine cathepsins, pro-
teases that have been identified as the most potent mammalian collagenases and
elastases that, upon secretion, locally degrade collagen, elastin, and other ECM
substrates.[208, 51] Cathepsins K, L, S, and V produced by macrophages and osteo-
clasts are highly implicated in atherosclerotic vascular remodeling as well as tumor
associated tissue remodeling.[115, 116, 157, 158, 184]
Pathologically overactive osteoclasts generate elevated levels of cathepsin K and
are the main etiological agents of osteoporosis and osteolytic lesions. Despite the
number of pharmacological inhibitors being developed to block this activity, many
are failing clinical trials.[99, 18, 36] This may be due to variability in cathepsin activ-
ity among patients, altering pharmacokinetics, and in turn, increasing side effects due
to under- or over-dosing. Studies have measured circulating cathepsin levels in pa-
tients with similar diseases and shown a wide range of variability, whether measured
in plasma or serum, among healthy or diseased patients.[113, 96, 94, 84, 2, 75, 159,
74, 134] In particular, computational analysis of dynamic changes in kinase activation
has shown that kinases serve as integrators of stimuli from different soluble, cellular,
and physical cues, to generate specific cellular responses.[77, 201, 101, 183] Predic-
tion of monocyte differentiation and resultant proteolytic activity from an individual
signaling pathway in isolation is problematic due to complex crosstalk in signaling net-
works, but is substantially improved when multiple pathways are considered.[134, 75]
A study used activation of just seven kinases in adult bone marrow-derived stem
cells to show that osteogenic differentiation decisions were encoded in temporal ki-
nase activation profiles, and analyzed them with the multivariate analytical technique
partial least squares regression (PLSR) to predict terminal differentiation outcomes
and phenotype.[159]
In the current study, we investigated if monocyte differentiation into macrophages
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or osteoclasts, and the resulting cathepsin activity of these cells were encoded in ki-
nase activation profiles, and if data-driven, multivariate analysis models could predict
donor-specific cell differentiation and proteolytic activity. We hypothesized that the
temporal kinase activation states would be predictive even with the challenge of incor-
porating complex unknown cues provided by the genetic and biochemical background
of each individual donor that leads to variability.
3.2 Methods
3.2.1 THP-1 Cell Culture
Human THP-1 acute monocytic leukemia cells (American Type Culture Collection
[ATCC]) were cultured in RPMI medium 1640 (Mediatech) containing 10% fetal
bovine serum (FBS, Atlanta Biologicals), 0.05% -mercaptoethanol, 1% L-glutamine,
and 1% penicillin/streptomycin (Life Technologies). Cells were maintained with 5%
CO2 at 37
◦C. For macrophage differentiation, monocytes were incubated with 100
nM phorbol myristate acetate (PMA, Sigma-Aldrich) for 24 h, followed by incuba-
tion for an additional 11 days in growth medium, with media changed twice per
week. For osteoclast differentiation, monocytes were incubated with 100 nM 1,25-
dihydroxyvitamin D3 (Alfa Aesar) for 12 days, with medium changed twice per week.
For all differentiation, cells were seeded at 300,000 cells/cm2.
3.2.2 Primary monocyte isolation and differentiation
Heparinized venous blood from healthy volunteers was diluted 1:1 in sterile PBS, lay-
ered on Ficoll-Paque (GE healthcare), and centrifuged at 400g for 30 minutes. The
buffy coat layer was isolated, red blood cells lysed, and peripheral blood mononu-
clear cells (PBMCs) were washed 3 times in PBS. Monocytes adhered overnight and
all other non-adherent cells were removed. For macrophage differentiation, isolated
monocytes were cultured in RPMI containing 10% male human serum and 30ng/µl
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macrophage colony stimulating factor (M-CSF, Peprotech). For osteoclast differen-
tiation, isolated monocytes were cultured in alpha-MEM (Life Technologies) supple-
mented with 10% fetal bovine serum, 30ng/µl M-CSF, and 30ng/µl receptor activator
of NFκB Ligand (RANKL) (Peprotech). Medium was replaced every 3 days.
3.2.3 TRAP Histological Staining
On day 15, both macrophages and osteoclasts were stained for tartrate-resistant acid
phosphatase (TRAP) activity according to the manufacturers instructions (Sigma-
Aldrich). TRAP activity was visualized under a light microscope as brown and dark
red areas. Multinucleated cells were deemed as those with three or more nuclei.
3.2.4 Flow Cytometry
TRAP activity was quantified using flow cytometry modified from an existing proto-
col and using Fast Red violet (Sigma Aldrich) instead of Fast Garnet GBC. Adherent
cells were released using 2 mM ethylene diamine tetraacetate (EDTA), fixed with
4% paraformaldehyde and permeabilized using 0.02% Triton X-100. Cells were then
incubated in 2X TRAP Staining Solution (8% of 12.5 mg/ml napthol-ASBI phos-
phate, 2% of 10 mg/ml Fast Red violet diluted in solution containing 50 mM MES,
50 mM Na Tartrate and pH at 6.3) at room temperature for 9 minutes. Reaction
was ended using ice cold PBS. TRAP activity was detected at 488 nm excitation, 610
nm short pass dichroic and measured through a 675±20 narrow bandpass filter. For
CD68 labeling, adherent cells were released using 2 mM ethylene diamine tetraacetate
(EDTA), fixed with 4% paraformaldehyde. Cells were incubated in mouse anti-CD68
antibody (Millipore) at 4 ◦C for 30 minutes. They were then incubated with don-
key anti-mouse Alexafluor 488 (Life Technologies) at 4 ◦C for 30 minutes. Data were
expressed as percent of the total cell population positive for CD68.
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3.2.5 Cell morphology measurements
Cell diameter and number of nuclei measurements were used for cell morphology. For
macrophages, 20 cells were measured per donor, and a single diameter was measured
for each cell. For osteoclasts, the number of cells measured varied from 5 to 20 as
only cells with more than 3 nuclei were included; due to their irregular shapes, the
narrowest and widest parts of each cell were measured and averaged to approximate
diameter.
3.2.6 Kinase phosphorylation analysis with Bioplex assays
Differentiating cells were lysed and total protein concentration was determined us-
ing microBCA assay (Pierce). Bioplexrbead kits (BioRad) were used according to
manufacturers instructions with 5 g protein from each sample. Phosphorylation of
ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), Akt (Ser473), p38 MAPK (Thr180/Tyr182),
JNK (Thr183/Tyr185), c-jun (Ser63), NFκB p65 (Ser536) and IκB-α (Ser32/Ser36) were
measured. Signal values for each phosphorylated kinase were normalized to the signal
detected in a master lysate prepared in bulk from pre-stimulated monocytes that was
used as a control for all assays. Signal values for each kinase were normalized between
0 and 1 by dividing by the maximum value over the entire 9 days for all treatments.
3.2.7 Partial least square regression (PLSR) analysis
M x N data matrix was generated with data from M donors and N kinase phospho-
rylation signals. Each column of the independent X matrix corresponds to a unique
input or signal: phosphorylated kinase signal from days 1, 3, 6, and 9, and each col-
umn of the dependent Y matrix corresponds to unique outputs. Each row represents a
unique donor and stimulation condition (i.e. donor 1- MCSF, donor 1-RANKL, donor
2- MCSF, etc.). All data was mean-centered and scaled to unit variance. SIMCA-P
(UMetrics) was used to solve the PLSR problem with the nonlinear iterative partial
least squares (NIPALS) algorithm.[52]
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3.2.8 Multiplex cathepsin zymography
Media was replaced with serum-free media on day 14 and incubated overnight. This
conditioned media was collected and concentrated using VivaSpin500 Centrifugal
Concentrator (Vivaproducts). Cellular protein was extracted in lysis buffer (20 nM
Tris-HCl at pH 7.5, 5 mM EGTA, 150 mM NaCl, 20 mM -glycerol-phosphate, 10
mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 0.1% Tween-20) with 0.1
mM leupeptin freshly added. Cathepsin zymography was performed on cell extracts
and on conditioned media as described previously.[202] Briefly, equal amounts of pro-
tein in non-reducing loading buffer were separated on 12.5% SDS-polyacrylamide gels
containing 0.2% gelatin at 4 ◦C. Enzymes were renatured and then the gels were incu-
bated overnight at 37 ◦C in acetate buffer, pH 4 with 1 mM EDTA and freshly added
2mM dithiothreitol. Gels were then rinsed, stained with Coomassie blue, and imaged
using an ImageQuant LAS 4000 (GE Healthcare). Densitometry was performed using
ImageJ to quantify the intensity of the white cleared band of proteolytic activity. For
cathepsin K inhibitor studies, gels were incubated overnight at 37 ◦C in the presence
of 1M cathepsin K inhibitor (1-(N-benzyloxycarbonyl-leucyl)-5-(N-Boc-phenylalanyl-
leucyl) carbohydrazide [Z-L-NHNHCONHNH-LF-Boc], EMD Biosciences) or vehicle.
[94]
3.3 Results
3.3.1 THP-1 monocyte differentiation into macrophages or osteoclasts is
encoded in temporal kinase activation states
Clonal THP-1 monocyte cells were used to identify a set of kinases for predicting
macrophage or osteoclast differentiation outcomes. These cells have been differenti-
ated into macrophages with phorbol 12-myristate 13-acetate (PMA) and into osteo-
clasts with 1,25α vitamin D3 (1,25 D3).[170, 70, 146, 89] We first confirmed this in
our hands by stimulating THP-1 cells with 100 nM PMA for 1 day, followed by 8
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days of culture, or 100 nM 1,25α vitamin D3 for 12 days. After 12 days, osteoclast
differentiation was confirmed by tartrate resistant acid phosphatase (TRAP) positive
staining and multi-nucleation (n≥3) as indicated by Hoechst staining (Figure 4A).
In parallel, lysates were collected on days 1, 4, 6, and 9 of differentiation for Bioplex
phosphorylated kinase assays. Six µg of total protein was used to quantify phospho-
rylation of Akt, ERK1/2, p38, IκB, and JNK at each of these time-points in cultures
stimulated with either PMA or 1,25 D3. These kinases were chosen as they have all
been implicated during monocyte differentiation into either macrophages, osteoclasts,
or both.[170, 168, 146, 15, 187] Kinase phosphorylation signals were normalized to the
maximum activation across all conditions for all time points and treatment conditions
(Figure 4B). The plots illustrate the difficulty in identifying patterns to link the cues,
signals, and responses of differentiating cells based on an individual pathway.
Quantitative measurements of macrophage and osteoclast differentiation were nec-
essary to populate a response matrix for the partial least squares regression (PLSR)
model, and establish a mathematical relationship between kinase phosphorylation
signatures and monocyte differentiation responses. To quantify macrophage differ-
entiation, flow cytometry was performed after labeling the cells with an anti-CD68
antibody. For osteoclasts, traditional, qualitative colorimetric TRAP staining was
modified with a fluorogenic phosphatase substrate to enable fluorescent TRAP activ-
ity quantification by flow cytometry.[44] As expected, there was a significantly greater
number of TRAP+ cells after stimulation with 1,25 D3 compared to the other two
conditions, while treatment with PMA significantly increased the percentage of cells
positive for CD68 expression (Figure 4C, n=3, p¡.01).
With quantitative signals from kinase phosphorylation measurements (Figure 4B)
and quantified differentiation responses from flow cytometry (Figure 4C), we were
then able to determine if these kinase activation states could be used to predict
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Figure 4: Multivariate analysis of kinase signals of THP-1 monocytes
predicts and distinguishes macrophage and osteoclast differentiation out-
comes. THP-1 monocytes were stimulated with 100nM PMA or 100nM 1,25 vitamin
D3 (1,25 D3) for 12 days. A) Nuclei were stained with Hoechst for determining multi-
nucleation (top row). Cells were fixed and stained with colorimetric TRAP activity
assay (bottom row). B) On days 1, 4, 7 and 9 of differentiation, macrophages and os-
teoclasts were lysed and kinase signals were quantified using Bioplex technology and
normalized to maximum signal over the time period. C) On day 12, flow cytometry
for TRAP activity and CD68 expression was performed. D) PLSR analysis was per-
formed using kinase signals and the scores plot shows polar separation of osteoclasts
(1,25 D3) and macrophages (PMA) along principle component 1 (PC1). E) The load-
ings plot shows polar separation of temporal kinase phosphorylation and covariance
with differentiation outcomes of osteoclasts (TRAP+) or macrophages (CD68).
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macrophage or osteoclast differentiation responses. Based on the principles of eigen-
vectors and orthogonal transformation, PLSR algorithm groups signals with co-varying
responses, and reduces dimensionality of the data by plotting them along principal
component (PC) axes that capture maximal variance. The PLSR algorithm then
computes a linear solution in principal component space based on the proposed re-
lationship between the independent variables X (signals) and dependent variables Y
(responses) to calculate a coefficient matrix such that Y=F(X) in principal compo-
nent space. Methods to determine significance of principal components is described
in supplemental methods. The kinase signals that co-vary the greatest with the
dependent variable (macrophage or osteoclast differentiation responses in this case)
are weighted more heavily in the solution function that will be used to predict the
responses (Y ) from the given input data matrix (X ). When analyzing biological mea-
surements, these principal component axes can be assigned to biological phenomena
such as differentiation, proliferation or apoptosis.
In the scores plot shown in figure 4D, treatment conditions are plotted onto prin-
cipal component axes according to their covariance. In other words, similar cellular
responses to treatments are grouped together when projected onto the principal com-
ponents. PMA and 1,25D3 stimulated kinase signatures were segregated along the
first principle component (PC 1). Undifferentiated THP-1 monocytes cultured only
in RPMI media were segregated along PC 2 from the differentiated cells. This sug-
gested that the first principal component could be defined as macrophage/osteoclast
differentiation axis, and the second as the proliferation axis. The loadings plot is
shown in figure 4E and depicts the contribution of an individual kinases activation at
a specific time, to macrophage or osteoclast differentiation according to the calculated
weighted coefficients, and plots them onto weighted principal components. A clear
polarization of signals with either CD68 or TRAP responses is depicted.
Goodness of prediction was tested using a bootstrapping approach; cross-validation
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was performed by omitting an observation, then using the calculated weighted coef-
ficient matrix to predict response values without those removed observations. This
procedure was repeated until every observation had been excluded exactly once. Then
predictability was determined using root mean square error between predicted and
experimentally observed values. Using Akt, ERK1/2, p38, IκB, and JNK phospho-
rylation, greater than 99% predictability of CD68 expression and TRAP positive
staining was achieved suggesting that these kinases would be useful in predicting
monocyte differentiation responses.
3.3.2 Primary monocyte-derived macrophages and osteoclasts from healthy
donors exhibit extensive morphological variability
The cell line was useful for proof-of-principle that a key set of kinase activation sig-
natures could be predictive of monocyte differentiation decisions. The next step was
to apply this methodology to primary monocytes isolated from different individuals
peripheral blood. Monocytes were isolated from healthy donors and stimulated for
macrophage differentiation with M-CSF for 14 days, or for osteoclast differentiation
with M-CSF and RANKL for 14 days. Morphological differences in diameter and
number of nuclei among the donors differentiated macrophages and osteoclasts were
the first indicator of variability among donors. Representative images of differenti-
ated cells are shown with donor matched macrophages and osteoclasts, by column
(Figure 5A). Osteoclast differentiation was confirmed by multi-nucleation (n ≥3) and
TRAP+ histological staining (Figure 5B).
Cell diameter and number of nuclei of monocyte derived macrophages and monocyte-
derived osteoclasts were quantified and shown in the box and whisker plots (Figure
5C). Mean diameter of the macrophages was 29.2±12µm, 41% deviation in diameter,
among seven donors, here on referred to as Group I, and with one nucleus. Osteoclasts
exhibited greater range of donor variability with a mean diameter of 143.5±85µm,
a 59% deviation, and median number of nuclei of 3 (Figure 5C) with one osteoclast
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from a particular donor contained as many as 9 nuclei, although the median number
of nuclei among all counted osteoclasts for that donor was 5. TRAP and CD68 expres-
sion were initially measured for first sets of samples using flow cytometry. However,
changes in forward and side scatter (FSC and SSC) due to these morphology differ-
ences made it difficult to reliably gate and quantify appreciable shifts in fluorescence
for these groups. Due to this, cell size and number of nuclei were used as quantitative
morphological measurements.
3.3.3 Donor-to-donor variability in cell morphology is encoded in tempo-
ral kinase activation states of the differentiating monocytes
We tested the hypothesis that a coefficient matrix could still be calculated from multi-
variate kinase activation to predict donor monocyte differentiation responses despite
the donor-specific morphological variability. Cell lysates were collected on days 1,
3, 6 and 9 of primary monocyte differentiation and temporal kinase phosphorylation
signatures were measured using Bioplex assays as described earlier. These kinase
activation signatures were variable for Group I, as indicated by color variations in
the heat map, even for the same kinase, treatment condition, and time (Figure 6A).
The input matrix (X ) of kinase phosphorylation and dependent response matrix (Y )
of cell morphology data of diameter and number of nuclei were used to calculate
the weighted coefficient matrix that would link the initiating cues to the differenti-
ated cell phenotype responses using the kinases signals. Separate models were made
for macrophages and osteoclast differentiation cues, with the inherent, but unknown
donor-specific factors that stimulate monocytes in vivo, affecting kinase signatures of
both datasets.
PLSR analysis also can identify the most important kinase signals and time points
for a differentiation outcome by calculating the variable importance for projection
(VIP) using a weighted sum of squares of the coefficients calculated for a signal, such
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Figure 5: Phenotypic variability of macrophages and osteoclasts derived
from peripheral blood monocytes Monocytes isolated from peripheral blood
were cultured for 14 days and treated with 30ng/µl M-CSF alone to differentiate
them into macrophages or with 30ng/µl M-CSF and 30ng/µl sRANKL to drive os-
teoclastic differentiation and cultured. A) Representative pictures of monocyte de-
rived macrophages and monocyte derived osteoclasts after 12 days of differentiation
are shown. Dotted lines outline osteoclasts. B) On day 15, multinucleated cells in
the culture were stained for TRAP activity to confirm osteoclastic differentiation. A
representative image of colorimetric assay staining is shown. C) Mean diameter and
average number of nuclei per donor were measured (n=7).
25
that those signals projecting strongly either positively or negatively with a differenti-
ation response are highly ranked. If the VIP value was greater than 1, then the kinase
signals were regarded as significant. JNK activation on days 1, 3 and 6 were important
for determining cell morphological responses for both macrophages and osteoclasts
(Table ??. Interestingly, the effects of JNK activation on macrophage and osteoclasts
were opposite; with a positive correlation for macrophage diameter but a negative
correlation for osteoclast diameter and number of nuclei. Using the bootstrapping
method described earlier, goodness of prediction was calculated. Predictability was
97% for cell diameter of macrophages, and 93% for osteoclasts. Predictability was
95% for number of nuclei for osteoclasts (Figure 6B). With only one nucleus, no
variation could be predicted for monocyte-derived macrophages.
To test this predictability a priori, this trained model was applied to 7 additional
donors, denoted as Group II, with kinase activation heat map and variable signals
shown (Figure 7A). Cell diameter was predicted at 90% and 92% for macrophages
and osteoclasts, respectively, but osteoclast nuclei predictability dropped to 71%
(Figure7B). Quantification of these experimental measurements for Group II is shown
in box and whisker plots with mean diameter of the macrophages as 34.4 10µm (29%
deviation) among 7 donors (Group II) and osteoclasts at a mean diameter of 173.9
54µm (31% deviation). Median number of nuclei for these osteoclasts was 4, one
higher than training Group I, but two donors from Group II had higher average num-
bers of nuclei (>6) which could have lowered the nuclei predictability (Figure7C).
3.3.4 Cathepsin proteolytic activity of differentiated macrophages and
osteoclasts reflect donor-to-donor variability
With some predictability of morphology, we tested if behavioral or functional activity
of the differentiated macrophages and osteoclasts could also be predicted for individ-
ual donors. Cathepsin activity was this metric. After the 14 day differentiation period
during which kinase phosphorylation data was collected, conditioned media and cell
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Figure 6: Donor-to-donor variability in macrophage and osteoclast differ-
entiation outcomes of cell diameter and number of nuclei is captured in
kinase activation state of differentiating monocytes A) On days 1, 3, 6 and
9 of differentiation, macrophages and osteoclasts were lysed, and kinase signals were
quantified using Bioplex technology. A compendium of time-dependent kinase sig-
nals of donors 1-7 (group I) is shown. Signals are normalized to the highest value
within a given time point and a kinase. White boxes correspond to missing mea-
surements. B) A PLSR model was generated with kinase signals of differentiating
macrophages as inputs and cell diameter as an output (R2Y = 0.734 Q2= 0.061, 1
significant PC). A separate PLSR model was generated for differentiating osteoclasts
with their kinase signals in input matrix and their cell size and number of nuclei in
output matrix (R2Y = 0.815, Q2 = 0.248, 2 significant PCs). Prediction was made
with cross-validation and jack-knifing approaches, and predictability was calculated
based on RMSEE. Plots of predicted vs. observed are shown, with blue diamonds for
osteoclasts and red diamonds for macrophages. Predictability for cell diameter was
96% for macrophages and 89% for osteoclasts. Predictability for number of nuclei
was 94% for osteoclasts. With only one nucleus, no variation can be predicted for
macrophage.
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Table 1: Variable importance of projection (VIP) for macrophage diameter
and osteoclast diameter and number of nuclei Kinase signals with significant
VIP values for the PLSR model predictive of macrophage diameter, and osteoclast
diameter and number of nuclei. Kinase signals were regarded as significant if the
VIP value was greater than 1. Kinase signals with significant VIP values for both
macrophages and osteoclasts were highlighted.
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Figure 7: A priori predictions of differentiated morphologies A) A com-
pendium of time-dependent kinase signals of donors 8-14 (group II) used for a priori
prediction is shown. B) The trained models for macrophages and osteoclasts gen-
erated with Group I data were used to predict cell diameter and number of nuclei
from Group II kinase data. The model was effective in predicting cell diameter, with
90% predictability for macrophages and 91% predictability for osteoclasts, but only
71% for osteoclast nuclei. With only one nucleus, no variation can be predicted for
macrophage. C) Experimental/observed quantification of mean diameter and average
number of nuclei per donor (n=7).
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extracts were collected and assayed for cathepsin activity from a separate group of
cells seeded from Group II donors. Multiplex cathepsin zymography was used. By
this assay, active cathepsins K, L, S, and V produce cleared white bands of degraded
gelatin on a Coomassie stained gelatin-polyacrylamide gel. Intensity correlates to
level of proteolytic activity and this can be quantified with densitometry. An added
benefit of this assay is that cathepsins K, L, S, and V all produce a detectable signal
on the same gel but appear at distinct, expected electrophoretic migration distances
of 37 kD for cathepsin K, 35 kD for cathepsin V, 25 kD for cathepsin S, and 20 kD for
cathepsin L.[82] It is also more sensitive for cathepsin K than Western blotting.[105]
Cathepsin activity from cell extracts (Figure 8A,B) and conditioned media (Fig-
ure 8C,D) was quantified, and donor variability is shown in the box and whisker plots
with representative gels of four donors zymograms shown. Zymograms shown in figure
5 were incubated at pH 4 for maximal cathepsin V and L signals, and were also incu-
bated at pH 6 for maximal cathepsin K signal[202] (Figure 9). From these zymogram
results, there were similar cathepsin activity profiles across donors within a cell type,
but distinctive between osteoclasts and macrophages. A 75 kD cathepsin activity
band consistently appeared in osteoclast lysates and conditioned media, suggestive of
it being cathepsin K activity. However, its electrophoretic migration distance differed
from the expected 37 kD distance for cathepsin K.[94] To verify its identity, osteo-
clast lysates were loaded for cathepsin zymography and incubated in the presence or
absence of 1µM cathepsin K inhibitor, which blocked the appearance of the band in
question after staining the zymogram, confirming its identity as cathepsin K (Figure
8E,F). Cathepsins K and V activity was higher in both conditioned media and cell
extracts of osteoclasts compared to macrophages. This was expected for cathepsin K
since it is the key enzyme used by osteoclasts for bone resorption.[23] Cathepsin V,
however, was more unexpected since its tissue localization has been reported as being
restricted to thymus, testis, cornea, and macrophages.[208] Macrophage cathepsin L
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activity was high in both conditioned media and cell extracts supporting reports of its
expression by macrophages in atherosclerosis.[115] Cathepsin L was not secreted by
osteoclasts, however, although it was active intracellularly. Cathepsin L also showed
the greatest donor-to-donor variability.
3.3.5 Donor-specific cathepsin proteolytic activity of monocyte-derived
macrophages and osteoclasts can be predicted
To test predictability of cathepsins K, L, S and V activity in differentiated macrophages
and osteoclasts, cell-type specific coefficient matrices were calculated using the pre-
viously collected kinase signatures from Group II. Predictability was calculated as
before with cell diameter and nuclei data, but this time for cathepsin activity in cell
extracts. Plots of predicted values versus experimentally observed values are shown
in (Figure10). Predictability for all cathepsins was greater than or equal to 90%,
and this was true for both macrophage and osteoclast outcomes. For macrophages,
predictability for cathepsin K was 90%, cathepsin V was 95%, cathepsin S was 94%,
and cathepsin L was 93% (Figure10A). For osteoclasts, predictability for cathepsin
K was 90%, cathepsin V was 90%, cathepsin S was 95%, and cathepsin L was 90%
(Figure10B). Predictions for cathepsins secreted into the conditioned medium were
generally lower than 90% and considered not to be predictive (Figure 11). Analysis of
the VIPs for predicting cathepsin activity identified c-jun phosphorylation as impor-
tant for cathepsin activity of monocyte-derived macrophages and osteoclasts (Supp
Table 2), and this has been implicated previously by us.[82]
3.4 Discussion
Variability in disease may be due to a number of factors. From these results, we sub-
mit that each persons individual biochemical milieu of cytokines, growth factors, and
other stimuli, contain a bevy of cues that explicitly and acutely pre-condition cells for
specific responses to induce the variability in response to treatment or in progression
31
Figure 8: Cathepsin proteolytic profiles of differentiated macrophages and
osteoclasts reflect donor-to-donor variability Multiplex cathepsin zymography
(assay buffer, pH 4) and quantification of (A, B) cell extracts or (C, D) conditioned
media for macrophage and osteoclast differentiation from donor monocytes. Quantifi-
cation of cathepsin activity and donor variability is represented in the box and whisker
plots. To confirm identity of 75kD band as cathepsin K, osteoclast lysates were loaded
for zymography and 1µM of cathepsin K inhibitor (1-(N-benzyloxycarbonyl-leucyl)-5-
(N-Boc-phenylalanyl- leucyl) carbohydrazide [Z-L-NHNHCONHNH-LF-Boc] was in-
cubated with the zymogram during the overnight incubation at pH 4 (E) or pH 6 (F).
The 75kD active band no longer appears.
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Figure 9: Cathepsin proteolytic profiles of differentiated macrophages and
osteoclasts in assay buffer, pH 6. Multiplex cathepsin zymography (assay buffer,
pH 6) and quantification of (A, B) cell extracts or (C, D) conditioned media for
macrophage and osteoclast differentiation from donor monocytes. Quantification of
cathepsin activity and donor variability is represented in the box and whisker plots.
As with zymograms incubated in pH 4, the 75kD cathepsin activity was apparent in
osteoclasts and cathepsin V activity was higher in osteoclasts as well. Cathepsin L
activity was higher in cell extracts of macrophages.
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Figure 10: Multivariate analysis of kinase activation successfully pre-
dicted donor-specific cathepsin proteolytic activity of monocyte derived
macrophages and osteoclasts Predictability of cathepsins K, L, S, and V activity
in cell extracts using a PLSR model trained with kinase measurements of differentiat-
ing macrophages (A) (R2Y = 0.837, Q2 = 0.618, 1 significant PC) or of differentiating
osteoclasts (B) (R2Y = 0.564, Q2 = -0.0823, 1 significant PC).
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Figure 11: Multivariate analysis of kinase activation was not highly predic-
tive of secreted cathepsin proteolytic activity of donor monocyte derived
macrophages and osteoclasts. Predictability of secreted cathepsins K, L, S, and
V activity using a PLSR model trained with kinase measurements of differentiating
macrophages (A) (R2Y = 0.693, Q2 = 0.541, 1 significant PC) or of differentiating
osteoclasts (B) (R2Y = 0.478, Q2 = 0.073, 1 significant PC).
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Table 2: VIPs for cell-associated cathepsin activity of macrophages and
osteoclasts Kinase signals with significant VIP values for the PLSR model predic-
tive of cell-associated cathepsin activity of monocyte-derived macrophages and for
monocyte-derived osteoclasts.
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of disease. Cathepsins are proteases expressed by macrophages and osteoclasts that
are also biomarkers and mediators of tissue destructive diseases. By using a systems
biology approach to link cell differentiation cues and responses through integration of
signals at the kinase level, where integration of ubiquitous information is processed
intelligently by the differentiating cell, we were able to mathematically predict rela-
tive amounts of cathepsin activity and distinguish which donors would have greater
cathepsin activity compared to others.
Despite stimulation with identical cues, in vitro, donor-to-donor variability was
evident in kinase activation signatures, differentiated cell morphology, and cathep-
sin activity. This suggests that there were additional cues that pre-conditioned the
circulating monocytes from unique, donor-specific milieus prior to isolation. Along
with a donors genetic background, there are many bioactive molecules circulating in
the blood that control macrophage and osteoclast differentiation, such as monocyte
chemoattractant protein-1, RANKL, tumor necrosis factor-, parathyroid hormone,
and calcitonin, among others, that differ from donor to donor. The complex question
of how to account for the influence of these undetermined and unmeasured cues may
be answered using kinase signatures, as demonstrated by this study. Kinases are up-
and downstream of growth factor binding to receptors, cytokine stimulation, tran-
scription factor binding, gene transcription, and protein translation. Therefore, by
measuring kinase activation as this nexus of inputs that precede outputs, predictive
information of cell fate prior to synthesis of differentiated cell-specific proteins and
behavioral responses is provided. Although there was variability in magnitude and
duration of kinase activation signals among the seven original donors of this study,
a weighted coefficient matrix could be used to calculate and predict the responses of
cell diameter and number of nuclei with as high as 97% predictability (Figure 6). Os-
teoclasts larger cell diameters and multi-nucleation are distinct characteristics from
macrophages, although they differentiate from the same progenitor cell. By using
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these metrics, PLSR was able to predict differentiation outcomes in terms of cell di-
ameter and number of nuclei. Even further, it was predictive of the donor-specific
differences in these outcomes, which varied by as much as 59% for osteoclasts (Figs
3 and 4).
This was tested a priori on a second group of donors with predictability remain-
ing above 90% for cell diameter, but an additional functional outcome of cathepsin
activity was measured to link the donor variability in differentiated macrophages
and osteoclasts to cell function; cathepsin activity from cell extracts was also highly
predictive using only temporal kinase signatures (Figure 10), and macrophage mod-
els were more predictive than osteoclasts. This is a limitation of the model, but it
makes sense considering the wider range of values for osteoclasts and the fact that
they are multi-nucleated cells formed from fusion of pre-osteoclasts. Another limi-
tation is that it was difficult to predict secreted cathepsin activity levels in a donor
specific manner (Figure 11). As an explanation, cathepsins are highly regulated at
multiple stages from transcription to translation to secretion, and are susceptible to
external influences such as degradation, oxidation, denaturation, and inhibition.[16]
Additionally, we have recently shown that cannibalism occurs between cathepsins in
the extracellular space serving to degrade each other,[7] and the time frame at which
conditioned media is collected could allow this additional behavior to occur and re-
duce the amount of secreted cathepsin present. These factors cannot be accounted
for by changes in intracellular kinases. The multivariate analysis was able to provide
clues to identify cathepsin K despite its altered electrophoretic migration. Cathepsin
K is post-translationally modified in several ways that can affect its electrophoretic
migration under non-reducing conditions: 1) its glycosylation can lead to altered tar-
geting and secretion,[16] 2) it binds to chondroitin sulfates to form large oligomeric
complexes,[107, 106, 108] and 3) there are also reports of cathepsin K assuming either
a tensed or relaxed state depending on ionic conditions at physiological pH that may
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be altering its electrophoretic migration.[149]
Development of cathepsins as biomarkers of disease is a growing field, but the
lack of predictability for secreted cathepsins shown in this study, may have trans-
lated to the difficulties of others that have used ELISAs to measure cathepsins in
plasma or serum and correlated their levels with disease. There have been var-
ied successes in cardiovascular disease, osteoporosis, cancer, and osteolytic bone
metastases.[113, 96, 94, 84, 2] Serum cathepsin K measurements have been contro-
versial; one study determined statistically significant elevated cathepsin K in post-
menopausal women with osteoporosis compared to healthy age matched women, even
though the standard deviation of the measurements was greater than the mean.[96] A
different study reported the opposite; serum cathepsin K levels could not be used to
identify pre- and post-menopausal women with osteoporosis or osteopenia.[96] In can-
cer biomarker studies, serum cathepsin levels have been measured for prostate, breast,
and lung cancer, and all have yielded wide range of donor to donor variability and in-
conclusive findings regarding their correlation with disease.[96, 191, 145] By studying
mononuclear cells from the blood and the proteases they will produce, inferences can
be made about local proteolytic activity contributing to the focal disease and matrix
degradation, whereas the circulating levels in the blood could be attributed to any
number of cells from different regions of the body. Those large cohort studies motivate
the need for personalized medicine approaches for individualized assessment incorpo-
rating the indefinable, therefore non-quantifiable patient-inherent factors that provide
cues to elicit cellular responses; these factors may explain why some individuals have
greater propensity to make proteolytic enzymes over others (Figure 8). In this study,
monocytes were specifically targeted as they are the effector cells that enter tissue,
differentiate, and advance disease. Recently, the effects of some inherent, circulat-
ing donor-specific factor (or a group of factors) that increased protease production
by monocytes was demonstrated in a comparative study between individuals with
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and without sickle cell disease.[82] In that study, we showed that the chronic inflam-
matory milieu of sickle cell disease activated monocytes to induce greater cathepsin
proteolytic activity after binding to endothelial cells compared to those without the
disease. This could be an example of donor-inherent factors that precondition mono-
cytes for elevated proteolytic activity. Although the donors of this current study did
not have sickle cell disease, they still exhibited wide range of variability in cathepsin
activity, perhaps due to each persons unique biochemical milieu; yet kinase activation
signals could predict these responses.
Donor variability in kinase activation signatures and cathepsin activity profiles
may provide insight into proper dosing and efficiency of therapeutic small-molecule
kinase inhibitors and cathepsin inhibitors currently in the pharmaceutical pipeline.
Variability among the donors kinase activation (Figure 6A, 7A) also suggests that
a one-size-fits-all approach of administering kinase inhibitors may not be the best
strategy for all patients. Certainly the varying levels of active cathepsins among
patients can be a confounding factor when prescribing doses of cathepsin inhibitors
and cause severe side effects in some patients, that have prematurely ended many
cathepsin S and K inhibitor clinical trials.[18]
3.5 Conclusions
Kinases are signal integrators between environmental cues and cellular responses,
and analysis of multiple kinase pathways yielded high predictability for monocyte
differentiation into macrophages and osteoclasts, described by cell morphology and
cathepsin activity. Although there are a myriad of donor-specific factors that cannot
be accounted for, we suggest that the wide range of donor-to-donor variability in
proteolytic expression from monocyte-derived macrophages and osteoclast shown in
our study may provide clues to wide range of disease progression and responses to
therapy observed between patients. Lastly, using data-driven, multivariate analysis
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model of kinases, we could predict donor-specific cathepsin activity profiles which
may provide beneficial tools for personalized protease inhibitor therapies.
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CHAPTER IV
DONOR-TO-DONOR VARIABILITY IN MACROPHAGE-
AND CATHEPSIN-MEDIATED BREAST CANCER CELL
INVASION
4.1 Introduction
Despite the prevalence of breast cancer in the U.S.[142], patient-to-patient variabil-
ity in disease progression continues to complicate clinical decisions in diagnosis and
treatment of patients.[179, 152, 27, 40, 153, 180, 204] Advancement in diagnostic and
imaging techniques led to increases in early detection of breast cancer. This increase,
however, often leads to premature and aggressive treatment of non-malignant lesions
due to inherent uncertainty in malignant progression of the cancer. A lack of well
informed risk/benefit analysis can result in net harm to the patients. This current
work turns to tumor microenvironment to identify potential patient-specific predictive
markers for cancer progression.
One main player that promotes invasiveness of cancer cells is tumor-associated
macrophages (TAMs).[58] TAMs have been shown to promote angiogenesis,[102, 103,
104, 37, 165, 131] tumor growth[103], invasion and metastasis[109] through secretion of
cytokines to coordinate tumor-promoting immune responses[6, 175, 120, 121] as well
as through secretion of tissue-remodeling cysteine cathepsin proteases.[56, 57, 138,
199, 167] Moreover, infiltration of TAMs is often associated with poor prognosis.[34,
97, 100, 22] Cathepsins secreted by TAMs have been shown to play significant role in
cancer growth and invasion.[56]
Previously, we showed donor-to-donor variability in cathepsin activity from pri-
mary monocyte-derived macrophages. In this current study, we investigate whether
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this variability in cathepsin activity leads to interdonor variability in macrophage-
mediated cancer cell invasion. donor MDMs were co-cultured with MCF-7 breast
cancer cell line, thereby limiting the variability in the system to donor-specific fac-
tors. We also seek to identify proteolytic or molecular signatures that could be useful
in identifying those with macrophages with high cathepsin activity and invasive po-
tential
4.2 Materials and Methods
4.2.1 Primary monocyte isolation and differentiation
Heparinized venous blood from healthy volunteers was diluted 1:1 in sterile PBS and
layered on Ficoll-Paque (GE healthcare) and centrifuged at 400g for 30 minutes. The
buffy coat was isolated, red blood cells lysed, and peripheral blood mononuclear cells
(PBMCs) were washed 3 times in PBS. For monocyte phosphoprotein and cathepsin
activity analysis, CD14+ and CD16+ monocytes were isolated using Pan-monocyte
magnetic bead isolation kit (Milteny) and lysates were collected. For macrophage
differentiation, monocytes adhered overnight were cultured in RPMI containing 10%
male human serum and 30ng/µl macrophage colony stimulating factor (M-CSF, Pe-
protech). Media was replaced every 3 days. For kinase inhibition studies, differentiat-
ing monocytes were treated with either 50µM JNK inhibitor II (SP600125, Millipore)
or 2.5µM LY294002 (PI3K inhibitor, Millipore) with media change every three days
for 12 days.
4.2.2 Multiplex cathepsin zymography
Cell extracts from monocytes and cell extracts and conditioned media from macrophages
were collected. To prepare conditioned media, differentiation media was replaced
with serum-free media on day 14 and incubated overnight. Conditioned media was
collected and concentrated using VivaSpinr500 Centrifugal Concentrator (Vivaprod-
ucts). Cellular protein was extracted in lysis buffer (20 nM Tris-HCl at pH 7.5, 5 mM
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EGTA, 150 mM NaCl, 20 mM β-glycerol-phosphate, 10 mM NaF, 1 mM sodium or-
thovanadate, 1% Triton X-100, 0.1% Tween-20) with 0.1 mM leupeptin freshly added.
Cathepsin zymography was performed on cell extracts and on conditioned media as
described previously.[202] Briefly, equal amounts of protein in non-reducing loading
buffer were separated on 12.5% SDS-polyacrylamide gels containing 0.2% gelatin at
4 ◦C. Enzymes were renatured and then the gels were incubated overnight at 37 ◦C
in phosphate buffer, pH6 with 1mM EDTA and freshly added 2mM DTT. Gels were
then rinsed, stained with Coomassie blue, and imaged using an ImageQuant LAS
4000 (GE Healthcare). Densitometry was performed using ImageJ to quantify the
intensity of the white cleared band of proteolytic activity
4.2.3 Measurements of cystatin C
Conditioned media collected from differentiated macrophages were loaded for Western
blot or ELISA to measure cystatin C level using mouse monoclonal antibody against
cystatin C (Santa Cruz Biotechnology) for Western blot and Quantikine Cystatin C
ELISA kit (R&D Biosystems).
4.2.4 Collagen invasion assay
Collagen invasion assay was adopted from a previous work by Goswami et al.[59]
On day 13, MDMs were stained using 25M CellTracker Blue CMAC (Invitrogen) for
90 minutes. Then MDMs (n=160,000) and MCF-7 cells (n = 64,000) were plated
on a 12-well MatTek multiwall plates in RPMI with 10% human AB serum. After
overnight incubation, cells were serum starved for 4 hours in serum-free RPMI. Then
cells were overlaid with 1,000µm layer of 2.5 mg/mL collage I and was allowed to gel
for 90 minutes at 37 C before adding 1mL of RPMI with 10% human AB serum. After
24 hour incubation, cells and the collagen gels were fixed with 10% neutral buffered
formalin and analyzed by confocal microscopy. Optical z-sections were taken every
5µm from the bottom of the plate. MCF-7 Cells that had invaded into collagen gel
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beyond 20µm were counted and were divided by the number of MCF-7 cells at the
bottom of the plate
4.2.5 Kinase phosphorylation analysis
On days 0, 1, 3, 6 and 9, freshly isolated monocytes or differentiating cells stimulated
with M-CSF were lysed and total protein was determined using BCA (Pierce). Bio-
plex bead kits (BioRad) were used according to manufacturers instructions with 5 g
protein from each sample and measured phosphorylation of ERK1/2 (Thr202/Tyr204,
Thr185/Tyr187), Akt (Ser473), p38 MAPK (Thr180/Tyr182), JNK (Thr183/Tyr185), c-
jun (Ser63), and IκB-α (Ser32/Ser36). Signal values for each phosphorylated kinase
were normalized to the signal detected in a master lysate prepared in bulk from pre-
stimulated cells that was used as a control for all assays. Signal values for each kinase
were normalized to between 0 and 1 by dividing by the maximum value over the entire
9 days for all treatments.
4.2.6 Partial least square regression analysis
M x N data matrix was generated with data from M donors and N kinase phos-
phorylation signals or N cathepsin activity and cystatin C level. Each column of
the independent X matrix corresponds to a unique input or signal: phosphorylated
kinase signal from days 0, 1, 3, 6, and 9, and each column of the dependent Y ma-
trix corresponds to unique responses which were cathepsin activity, cystatin C level
or invasion index. Each row represents a unique donor and stimulation condition
(i.e. donor 1-DMSO, donor 1-JNK inhibitor, donor 1-PI3K inhibitor, etc.). All data
was mean-centered and scaled to unit variance. SIMCA-P (UMetrics) was used to




4.3.1 Donor-to-Donor variability in macrophage cathepsin activity and
cystatin C level underlie interdonor variability in cancer cell inva-
sion
In our previous study, we reported donor-to-donor variability in cathepsin activity
of monocyte-derived macrophages. Because many studies have shown that tumor-
associated macrophages and cathepsins promote cancer cell invasion, we investigated
whether the variability in macrophage cathepsin activity we observed would lead to
variability in macrophage-mediated cancer cell invasion. Monocytes were isolated
from peripheral blood drawn from healthy donors using density gradient centrifu-
gation and were stimulated with M-CSF for 14 days. On day 14, differentiated
macrophages were plated onto a transwell coated with Matrigel with or without MCF-
7 breast cancer cells for modified Boyden chamber assay. After 24 hours, the number
of invaded cells was counted and invasion index was calculated. Invasion index was
defined to be the ratio between the number of invaded cells in the co-culture system
to the number of invaded cells in MCF-7-only culture. There was donor-to-donor
variability in the number of invaded cancer cells (Fig 12A). Cancer cells co-cultured
with macrophages from P3 invaded four times less than the cancer cells co-cultured
with donor 4 and twice less than donor 2. As the cancer cells were from clonal popu-
lation of MCF-7 breast cancer cell line, to determine whether the variability was due
to cathepsin secreted by macrophages, conditioned media was collected from the dif-
ferentiated macrophages after 14 days and an equal amount of protein was loaded for
multiplex cathepsin zymography (Fig 12B). Although there was apparent variability
in secreted cathepsin activity between donors, donor 3 who had the least invasion had
the highest cathepsin activity and donor 4 and 5 with high number of invaded cells
had low cathepsin activity. These results were in contradictory to studies that showed
cathepsins secreted by macrophages promote cancer cell invasion. However, it was
also shown that lack of cystatin C, an endogenous inhibitor of cathepsins, increases
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cancer cell invasion. We therefore turn to measure the amount of cystatin C secreted
by macrophages as studies have shown that lack of cystatin C can promote cancer cell
invasion. [148] The amount of cystatin C in conditioned media was measured using
Western blot and shown in figure 12C. As suspected, donor 3 who had the highest
macrophage cathepsin activity but the least invasion also had the highest amount
of cystatin C which could inhibit cathepsin activity in the system leading to lower
invasion of cancer cells.
A study showed that activation of JNK/c-Jun[83] stimulates cathepsins activity.
To investigate their role in mediating donor-specific differences in cathepsin activity
and invasion, we collected monocyte lysates on days 1, 3, 6 and 9 and measured
phosphorylation of six kinases: ERK1/2, Akt, p38 MAPK, JNK, c-jun and IkB-a. In
order to identify kinase signals that contribute most significantly toward proteolytic
and invasion outcomes, we trained a PLSR model where kinase signals were a signaling
matrix (X ) and the outcomes were the response matrix (Y ). Based on calculation of
VIP scores, phosphorylation of JNK/c-Jun and Akt was determined to be important
in determinining the outcomes. Activation of Akt has been associated with either
increase[86] or decrease[209] in cell motility and invasion.
4.3.2 JNK inhibition reduces macrophage cathepsin activity and cystatin
C level specifically among the subset of donors with high cathepsin
activity
Based on the VIP scores as well as on previous studies that suggested role of JNK
activation in cathepsin activity, we tested the hypothesis that inhibiting JNK/c-Jun
pathway will reduce macrophage cathepsin activity and subsequent invasion of cancer
cells. Freshly isolated monocytes from 12 donors were treated with SP600126 (50µM,
JNK inhibitor II, EMD Millipore) for 14 days. The inhibitor was added freshly with
each media change on days 1, 3, 6 and 9. On day 14, differentiation media was re-
placed with serum free RPMI and lysates and conditioned media were collected after
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Figure 12: Interdonor variability in cancer cell invasion is mediated by
donor-to-donor variability in macrophage cathepsin activity and cystatin
C level (A) Monocytes isolated from five donors among the first set were stimulated
with M-CSF for 14 days to differentiated them into macrophages. Conditioned media
was collected from days 14-15 and loaded for cathepsin zymography to measure se-
creted cathepsin activity which was quantified through densitometry. (B) On day 14,
differentiated macrophages were plated onto a transwell inserts coated with Matrigel
with or without MCF-7 breast cancer cells. After 24 hours, number of invaded breast
cancer cells were counted and invasion index was calculated. (C) The amount of cys-
tatin C in conditioned media was measured using Western blotting. (D) On days 1,
3, 6 and 9, differentiating monocytes were lysed, and kinase signals were quantified
using Bioplex technology.
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Figure 13: JNK inhibition reduces macrophage cathepsin activity and cys-
tatin C level specifically among subset of donors with high cathepsin activ-
ity Freshly isolated monocytes from the same 5 donors were treated with SP600126
(50µM, JNK inhibitor II, EMD Milipore) or LY294002 (2.5µM, PI3K inhibitor, EMD
Milipore) for 14 days. The inhibitor was added freshly with each media change on
days 1, 3, 6 and 9. On day 14, differentiation media was replaced with serum free
RPMI and lysates and conditioned media were collected after incubating cells for
14-16 hours. Cathepsin activity was measured using multiplex cathepsin zymography
(A) and cystatin C level was measured with ELISA (R&D Systems) (B).
incubating cells for 14-16 hours. Cathepsin activity was measured using multiplex
cathepsin zymography and cystatin C level was measured with ELISA (R&D Sys-
tems). There was a significant decrease in secreted cathepsin activity in macrophages
from 4 out of 12 donors. Additionally, macrophages from 2 other donors showed a
trend toward reduction in secreted cathepsin activity (Figure 13A). Interestingly, four
of these donors had the highest cathepsin activity before inhibiting JNK. Cystatin C
was reduced in macrophages isolated from donors 1, 3 and 11 (Figure 13B). No clear
correlations were found between JNK regulation of cathepsin and cystatin C.
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4.3.3 JNK inhibition reduced MDM-mediated cancer cell invasion for
highly invasive donors
As was shown earlier, both cathepsin activity and cystatin C levels from macrophages
influence cancer cell invasion. Therefore, we tested the hypothesis that the macrophages
with high cathepsin activity or low cystatin C level will have the highest invasive po-
tential. Differentiated macrophages treated with JNK inhibitors were co-cultured
with MCF-7 breast cancer cells for collagen I invasion assay. After treating differen-
tiating monocytes with JNK inhibitor for 13 days, as described earlier. On day 13,
macrophages were stained with CellTracker Blue CMAC (Invitrogen) and plated with
MCF-7 breast cancer cells. On day 14, following serum starvation for 4 hours, cells
were overlayed with 2.5mg/ml collagen I (Invitrogen) and media was added. After 24
hours, the collagen discs were fixed and the percentage of breast cancer cells invading
at least 20 µm into the collagen was determined by taking 5µm optical sections with
a confocal microscope (Figure 15). Inhibiting JNK in differentiating macrophages
reduced invasion of cancer cells co-cultured with macrophages from donors 8, 10 and
11. Their macrophages had the greatest invasive potential before JNK inhibition.
4.3.4 JNK inhibition reduces interdonor variability in macrophage cathep-
sin activity
Based on the results regarding donor-specific decreases in cathepsin activity after JNK
inhibition, we re-examine the effects of JNK inhibition for all donors as one cohort,
instead of for each donor. Population variance between the two groups were compared
using Brown-Forsythe test and variance was shown to be significantly reduced after
JNK inhibition (Figure 16 A). Variability in Cystatin C level was not affected by JNK
inhibition, but there was slight reduction in cancer cell invasion. To test that this
reduction in variance is specific to JNK inhibition, we inhibited Akt, another kinase
with high VIP scores, in differentiating monocytes and measured cathepsin activity,
cystatin C level and invasion. There was no significant change in the variance with
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Figure 14: JNK inhibition significantly reduced MDM-mediated cancer cell
invasion for highly invasive donors (A, B) After inhibiting JNK in differentiating
monocytes for 12 days, monocyte-derived macrophages were co-cultured with MCF-
7 breast cancer cell line for collagen I invasion assay. MDM-mediated cancer cell
invasion was significantly reduced among the donors with highest invasion (donors 8,
10 and 11).
51
Akt inhibition.(Figures 16 B, C). A scores plot of PLSR model trained with cathepsin
activity, cystatin C level and invasion shows clustering of macrophages treated with
JNK inhibitors (Figure 16 D).
4.3.5 JNK inhibition selectively reduces cathepsin activity and invasion
for donors with JNKlow monocytes
Because JNK inhibition reduced macrophage cathepsin activity and cancer cell in-
vasion among the donors with high cathepsin activity, we investigated if there are
distinguishing characteristics of circulating monocytes that can be identified without
differentiating them into macrophages for multiple days. We hypothesized that the
donor macrophages with higher cathepsin activity will have high monocyte cathep-
sin activity and JNK activation. To test this, we isolated monocytes from all 12
donors using magnetic activated cell sorting and lysed the cells to measure their
cathepsin activity and activated kinase signals. Monocytes isolated from donors 8,
9, 11 and 12 had high cathepsin activity but no detectable amount of activated
JNK (Figure 16A). P10 also had no detectable amount of activated JNK but also
no monocyte cathepsin activity. These results suggest although there is no apparent
correlation between monocyte and macrophage cathepsin activity, for the donors with
p-JNKlow monocytes, inhibiting JNK in macrophages reduces cathepsin activity as
well as macrophage-mediated cancer cell invasion.
4.4 Discussion
In the current study, we show that interdonor variability in cancer cell invasion is
associated with the donor variability in macrophage cathepsin activity and cystatin
C level. Although we acknowledge that the tumor microenvironment is extremely
diverse in terms of cellular population, cytokines, and growth factors, we were able
to isolate the effects of variability in donor macrophage phenotype on cancer cell
invasion by creating an in vitro model of cancer cell invasion where these facets can
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Figure 15: JNK inhibition reduces donor-to-donor variability in
macrophage cathepsin activity (A) When macrophage cathepsin activity, cys-
tatin C levels and cancer cell invasion were compared between treatment groups for
the entire donor cohort, there was significant reduction in macrophage cathepsin ac-
tivity after JNK inhibition as well as significant different in variance between the
two groups. PI3K did not reduce cathepsin activity significantly (B, C) Inhibiting
JNK or PI3K did not reduce cystatin C level or invasion significantly for the entire
cohort. (D) A PLSR scores plot for a model trained with cathepsin and cystatin C
level as signals and invasion as a response depicts the reduction in donor variability
in macrophage phenotype upon JNK inhibition
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Figure 16: JNK inhibition reduces macrophage cathepsin activity and can-
cer cell invasion among donors with p-JNKlow monocytes (A) Freshly isolated
monocytes were lysed for multiplex cathepsin zymography or Bioplex kinase assays
to measure cathepsin activity or kinase activation. Three kinases that were impor-
tant for macrophage cathepsin activity are shown in the heat map. (B, C) Cathepsin
activity and invasion was reduced significantly among donors 8, 9, 10, 11 with low to
undetectable level of activated JNK.
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be controlled and limited.When the effects of JNK inhibition were examined across
all the donors as one cohort, only cathepsin activity was shown to be decreased,
but other donor-specific responses for cystatins and invasion were masked by the
population variance. However, upon examining individual responses, we were also
able to reduce invasion among donors whose macrophages have high invasive potential
by inhibiting JNK/c-Jun pathway in differentiating monocytes. Notably, inhibiting
JNK increased invasive potential for macrophages from donor 2. This finding may
have important implications for personalized medicine approaches as although donor
cohort studies reveal important mechanistic information, each donor, especially those
who are outliers need to be examined individually for accurate diagnosis or treatment.
Moreover, with the increased development of small molecule inhibitors to treat cancer,
which modulate receptor kinase domains that are upstream of JNK such as EGF
receptor tyrosine kinase inhibitors, it is crucial to understand the off-target effects on
these inhibitors on other constituents of tumor tissues including TAMs. Alterations in
those upstream targets could reduce or enhance pro-tumorigenic properties of TAMs
on donor-specific basis.
We also showed that although cysteine cathepsins from macrophages are impor-
tant determinants of cancer cell invasion, ratio between macrophage and cystatin C
also contributes toward invasion. It is not known whether there is any transcriptional
or signaling feedback mechanism between cathepsins and their inhibitor cystatins.
This mechanism should be investigated further as the implications for this mechanism
in regards to proper dosing of the inhibitors to minimize adverse effects extend far
beyond treatment of cancer. Cathepsin inhibitors have been suggested for adjuvant
therapy for cancer and many other cathepsin inhibitors are in clinical trials to treat
osteoporosis as well as inflammatory and autoimmune diseases. [24, 39, 45, 154, 12]
Not much is known about the signaling pathways that regulate cathepsin activity
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and cystatin C levels or whether their regulation is connected. A study showed TNF-
alpha increases cathepsin activity in endothelial cells via JNK pathway.[83] From the
current study, we observe that inhibiting JNK decrease macrophage cathepsin activ-
ity for the donor cohort and cystatin C for selected donors suggesting a potential
connection between JNK and cystatin C expression. The JNK pathway has been
implicated in macrophage differentiation and polarization.[150, 68, 65] Although it is
not in the scope of the current study, when expression of macrophage marker CD68
was examined using flow cytometry for donor 3 in the cohort, more than 90% percent
of the macrophages treated with JNK and PI3K inhibitor expressed CD68. These
cells also seemed to exhibit different macrophage subtypes between the treatment
groups, suggesting that JNK inhibition may drive them toward M2-phenotype and
Akt inhibition toward M1-phenotype. Studies on cysteine cathepsin expression in dif-
ferent macrophage subtypes is limited but can have interesting implications not only
in cancer but other diseases such as atherosclerosis, where M1 and M2 macrophages
either contribute to or protect against disease development and progression
Lastly, we also show that individuals with p-JNKlow circulating monocytes had
the greatest macrophage cathepsin activity and invasion potential and these were sig-
nificantly reduced upon JNK inhibition. This finding suggests that subset of patients
may benefit from multifactorial screening that will include not only profiling tumor




PROTEOLYTIC PROFILE OF M1/M2 MACROPHAGES
AND INTERPATIENT VARIABILITY IN MACROPHAGE
POLARIZATION
5.1 Introduction
Tumor associated macrophages (TAMs) that are differentiated from circulating mono-
cytes promote angiogenesis,[102, 103, 104, 37, 165, 131] tumor growth[103], invasion
and metastasis[109] through secretion of tissue-remodeling cathepsin proteases and
cytokines to coordinate tumor-promoting immune responses.[6, 175, 120, 121] More-
over, infiltration of TAMs is often associated with poor prognosis.[34, 97, 100, 102,
22] When stimulated by distinctive cytokines, monocytes differentiate into tumor-
suppressive M1 type macrophages or tumor-promoting M2 type macrophages [175],
the latter being the dominant phenotype of TAMs.[175, 125] TAM/M2 type macrophages
express CD206 and CD163 on their surface and secrete immunosuppressive cytokines
such as IL-10[211], transforming growth factor-β (TGF-β), CCL18[91] and CCL225.
Unlike their counterpart, M1 macrophages are potent tumor-suppressing cells that
express CCR7 on their surface and produce iNOS, IL-1β and TNFα.[124] Functional
correlations between M1/M2 phenotypes, their cathepsin protease activity profile,
and the consequences this profile has in supporting or suppressing tumor growth
remain to be investigated.
In atherosclerosis, monocytes differentiate and polarize into M1 or M2 macrophage
subtypes in vascular walls based on the cues they have received from their environment.[140]
Studies suggest that M2 (or alternatively activated) macrophages are anti-inflammatory
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and anti-atherosclerotic, whereas, M1 (or classically activated) macrophages are pro-
inflammatory and pro-atherosclerotic.[13, 14, 166, 126, 67] As atherosclerotic plaque
development progresses, the population balance shifts from M2 macrophage-dominant
to M1 macrophage-dominant[85] suggesting that the balance between M1 and M2
macrophages are important for the progression and severity of atherosclerosis.[123]
Protease activity profiles of different macrophage subtypes that remodel vascular tis-
sue also remain to be elucidated
It is not known whether there is interpatient variability in M1/M2 macrophage
ratio. Also unknown is its implication on type of disease different individuals are
susceptible to, or on their propensity for greater tissue remodeling and disease pro-
gression. However, based on the findings that TAMS with M2 phenotype secrete
cathepsins to promote tumor growth and our finding showing interpatient variability
in macrophage cathepsin activity, we test they hypothesis that M2 macrophage have
greater cathepsin activity and that the patients with greater macrophage cathepsin
activity have a lower M1/M2 ratio.
5.2 Materials and Methods
5.2.1 Primary monocyte isolation, differentiation and polarization
Heparinized venous blood from healthy volunteers was diluted 1:1 in sterile PBS, lay-
ered on Ficoll-Paque (GE healthcare), and centrifuged at 400g for 30 minutes. The
buffy coat layer was isolated, red blood cells lysed, and peripheral blood mononu-
clear cells (PBMCs) were washed 3 times in PBS. Monocytes adhered overnight were
cultured in RPMI containing 10% male human AB serum and 30ng/µl macrophage
colony stimulating factor (M-CSF, Peprotech). Medium was replaced every 3 days.
In some cases, differentiating macrophages were stimulated with IFNγ +/- LPS for
M1 polarization and with IL-4 for M2 polarization in addition to M-CSF.
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5.2.2 Flow cytometry
To determine M1/M2 polarization, macrophages were differentiated for 14 days, fol-
lowed by harvesting and collection via centrifugation on day 15. Fc receptors were
blocked using blocking buffer solution (Biolegend Human TruStain FcXTM) for 10
minutes in room temperature. Cells were then labeled with the following antibodies:
PE-Cy5-CD11b, PE-CD163, APC-CD206, APC-Cy7-CCR7 (Biolegend) for 20 min-
utes in 4 ◦C in the dark. Cells were washed twice, then fixed with 4% formaldehyde
for 20 minutes in the dark at room temperature. Following permeabilization using
0.02% Triton X-100, cells were stained with FITC-CD68 (Biolegend). Either isotype
controls or Fluoresecnet Minus One (FMO) controls were used for fluorescence com-
pensation. Cells were analyzed using BD LSRII, BD Aria Cell Sorter or BD Accuri
and sorted using BD FACSAria (BD Biosciences).
5.2.3 Multiplex cathepsin zymography
Cell extracts from monocytes and FACS-sorted macrophages along with conditioned
media from macrophages were collected. To prepare conditioned media, differentia-
tion media was replaced with serum-free media on day 14 and incubated with the cells
overnight. Conditioned media was collected and concentrated using VivaSpinr500
Centrifugal Concentrator (Vivaproducts). Cellular protein was extracted in lysis
buffer (20 nM Tris-HCl at pH 7.5, 5 mM EGTA, 150 mM NaCl, 20 mM β-glycerol-
phosphate, 10 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 0.1% Tween-
20) with 0.1 mM leupeptin freshly added. Cathepsin zymography was performed on
cell extracts and on conditioned media as described previously.[202] Briefly, equal
amounts of protein in non-reducing loading buffer were separated on 12.5% SDS-
polyacrylamide gels containing 0.2% gelatin at 4 ◦C. Enzymes were renatured, and
the gels were incubated overnight at 37 ◦C in phosphate buffer, pH 6, with 1 mM
EDTA and freshly added 2mM DTT. Gels were then rinsed with dH2O, stained with
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Coomassie blue, and imaged using an ImageQuant LAS 4000 (GE Healthcare). Den-
sitometry was performed using ImageJ to quantify the intensity of the white cleared
band of proteolytic activity.
5.3 Results
5.3.1 Interpatient variability in expression of M1/M2 phenotypic markers
Freshly isolated monocytes were differentiated into macrophages with M-CSF for 14
days. Cells were collected and labeled with monocyte/macrophage markers (CD11b
and CD68), a M1 macrophage marker (CD197 or CCR7) and M2 macrophage markers
(CD206 or mannose receptor and CD163). The expression level was measured using
flow cytometry. Although M-CSF has been shown to promote M2 polarization,[127,
73] our results show that differentiated macrophages express both M1 and M2 markers
with varying degrees of expression between donors (Figure 17).
5.3.2 IL-4 stimulation increases both mannose receptor (M2 marker) and
CCR7 expression level (M1 marker)
Based on our finding that there are mixed subpopulations of macrophages for individ-
ual donors, we hypothesized that monocytes have been pre-conditioned by circulating
factors prior to isolation. We stimulated differentiating monocytes with IL-4 which
is known to promote M2 polarization. After 14 days, cells were collected and labeled
with M1/M2 surface markers, and expression levels were measured using flow cy-
tometry. IL-4 stimulation increased expression of CD206 (M2 marker) but decreased
expression of another M2 marker CD163 (Figure 18 A,B) . Surprisingly, IL-4 stim-
ulation also increased expression of M1 polarization marker CD197 (CCR7) (Figure
18 B).
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Figure 17: Interpatient variabiltiy in expression of M1/M2 macrophage
markers.Freshly isolated monocytes from 4 donors were simulated with 30ng/ml M-
CSF for 14 days. Expression level of macrophage polarization markers were measured
using flow cytometry. Among CD11b+/CD68+ macrophages, percentage of cells
expressing CD163 (M2 marker), CD197 (CCR7, M1 marker) or CD206 (mannose
receptor, M2 marker) was measured and compared between donors. There were cells
expressing more then one marker.
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Figure 18: IL-4 stimulation increases mannose receptor and CCR7 expres-
sion level but decrease CD163 expression Freshly isolated monocytes were stim-
ulated with both M-CSF and IL-4 for 14 days as they differentiated into macrophages.
(A) Co-stimulation with M-CSF and IL-4 increased the number of cells expressing
CD206, but decreased CD163 expressing cells, both of which are M2 polarization
markers. (B)IL-4 stimulation also increased CD197 (CCR7) which is known to be a
M1 polarization marker.
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5.3.3 M2 macrophages have higher cathepsin V and S activity; M1 macrophages
have higher cathepsin L activity
Although M1 macrophages are traditionally known to be pro-inflammatory and M2
macrophages anti-inflammatory, not much is known about their distinct proteolytic
profile. To investigate this, freshly isolated monocytes from 3 donors were stimulated
with 30ng/ml M-CSF alone, 30ng/ml M-CSF + IL-4, M-CSF + IFN-γ or M-CSF +
IFN-γ + LPS for 14 days as they differentiated into macrophages. On day 15, lysates
were collected and loaded for multiplex cathepsin zymography. The amount of active
cathepsins was quantified with densitometry and averaged across all three patients.
As a population, IL-4 stimulation increased the amount of active 35kDa, 25kDa and
20kDa cathepsins. IFN-γ stimulation increased active 25kDa cathepsin level, while
IFN-γ + LPS decreased active 35kDa and 25kDa cathepsins, but increased active
20kDa cathepsin level. (Figure 19)
5.3.4 IFN-γ stimulation increases cystatin C level.
In tissues, the amount of cathepsins that are proteolytically active is determined not
only by the concentration of cathepsins but also by the amount of cystatin C bound
to cathepsins which inhibits cathepsin activity. Therefore, we next measured cystatin
C levels from conditioned media of differentiated and polarized macrophages. After
stimulating differentiating monocytes with M-CSF alone, M-CSF + IL-4, M-CSF +
IFN-γ, or M-CSF + IFN-γ + LPS for 14 days; conditioned media was collected from
day 14-15, concentrated, and loaded for Western blotting to measure cystatin C level.
IFN-γ stimulation increased cystatin C protein expression level. (Figure 20)
5.4 Discussion
Here we showed that there is patient-to-patient variability in macrophage polarization
upon stimulation with M-CSF, a differentiation and survival factor for macrophages.
We also showed that stimulating differentiating monocytes with IL-4, a cytokine
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Figure 19: M2 macrophages have higher cathepsin V and S activity; M1
macrophages have higher cathepsin L activity Freshly isolated monocytes from
donors were stimulated with M-CSF alone, M-CSF + IL-4 for M2 polarization, M-
CSF + IFN-γ, or M-CSF + IFN-γ + LPS for M1 polarization for 14 days as they
differentiated into macrophages. On day 15, lysates were collected and loaded for
multiplex cathepsin zymography. The amount of active cathepsins was quantified.
IL-4 stimulation increased the amount of active 35kDa, 25kDa and 20kDa cathepsins.
IFN-γ stimulation increased active 25kDa cathepsin level, and IFN-γ + LPS decreased
active 35kDa and 25kDa cathepsins, but increased active 20kDa cathepsin level.
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Figure 20: IFN-γ stimulation (promoting M1 polarization) increases cys-
tatin C level Freshly isolated monocytes from donors were stimulated with M-CSF
alone, M-CSF + IL-4 for M2 polarization, M-CSF + IFN-γ, or M-CSF + IFN-γ +
LPS for M1 polarization for 14 days as they differentiated into macrophages. On day
15, secreted cystatin C level was quantified using Western Blotting. IFN-γ stimula-
tion, which promotes M1 polarization, increased cystatin C level.
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known to drive M2 polarization, or IFN-γ, a cytokine known to drive M1 polarization,
generates mixed population of M1/M2 macrophage cells, albeit there is dominant
subtype. We also observed cells that co-express traditional M1/M2 markers. This
finding is in line with the shifting paradigm in macrophage polarization that rather
than the M1/M2 dichotomy, macrophages exist on a continuous spectrum.[140]
Roles of different macrophage subtypes in health and disease have been studied
extensively.[174, 122] However, there is a gap in the knowledge of the proteolytic pro-
file of different macrophage subtypes. As the macrophage subtypes, as well as cysteine
cathepsins, play distinct roles at different stages of tissue-remodeling diseases includ-
ing cancer and atherosclerosis, it would be greatly beneficial to better understand their
remodeling capacity. Findings from this study showed that M2-phenotype, driven by
IL-4 stimulation, has greater cathepsin V and S activity, whereas M1-phenotype,
driven by IFN-gamma, has higher cathepsin L activity. With the finding that some
patients have greater expression of M1 or M2 markers, one potential mechanism un-
derlying interpatient variability in macrophage cathepsin activity we have identified
is differential make up of M1/M2 macrophages between patients. With further stud-
ies to correlate M1/M2 ratio and the net protease activity with measurable disease




VARIABILITY IN MONOCYTE CATHEPSIN ACTIVITY
AMONG PATIENTS WITH BREAST CANCER
6.1 Introduction
Approximately one in eight women in the United States will develop invasive breast
cancer over the course of her lifetime.[142] Despite significant advances in breast can-
cer therapies, patient-to-patient variability in disease progression continues to com-
plicate clinical decisions in diagnosis and treatment.[179, 152, 27, 40, 153, 180, 205] A
recent study showed that the incidence of breast cancer overdiagnosis may be as high
as 30%.[11] Many more studies and commentaries followed suggesting that the inci-
dence of overdiagnosis is prevalent only among ductal carcinoma in situ (DCIS), a
benign form of breast tumor that has potential to become invasive cancer. Cur-
rently, there is no accurate method to predict that invasive potential, and some
women decide to undergo radical mastectomy to prevent malignant progression. Un-
til recently, many studies have focused on identifying characteristics of cancer cells
themselves. However, it has become clear that tumor microenvironment, which en-
compasses tumor cells, stromal cells, recruited immune cells, including tumor as-
sociated macrophages (TAMs) plays crucial roles in determining behavior of can-
cer cells.[111, 43, 48, 28] TAMs that are differentiated from circulating monocytes
promote angiogenesis,[102, 103, 104, 37, 165, 131] tumor growth[103], invasion and
metastasis[109] through secretion of cytokines to coordinate tumor-promoting im-
mune responses[6, 175, 120, 121] as well as through secretion of tissue-remodeling
cathepsin proteases. Moreover, infiltration of TAMs is often associated with poor
prognosis.[34, 97, 100, 102, 22]
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We have shown that in healthy donors, there is donor-to-donor variability in
macrophage cathepsin activity, which contributes to variability in cancer cell inva-
sion. Moreover, we have shown that for the donors with monocytes with low JNK
activation, inhibiting JNK in during monocyte-to-macrophage differentiation reduces
co-cultured cancer cell invasion. With that knowledge, now we investigate patient-
variability in monocyte cathepsin activity and kinase activation state for women di-
agnosed with various stages of breast cancer the long-term goal of this study is to
find early and non-invasive markers to identify patients who may develop invasive
breast cancer. The hypothesis is that interpatient variability in monocyte kinase
signatures and cathepsin activity persists despite disease-related cues that modify
cellular behavior.
6.2 Materials and Methods
6.2.1 Patients
Peripheral venous blood and breast tissues were obtained from female patients who
are undergoing mastectomy. Patients were diagnosed with various stages of breast
cancer including DCIS and invasive ductal carcinoma (IDC). Informed consent was
obtained prior to surgery and is in accordance with protocol approved by Georgia
Institute of Technology and Dekalb Medical Center (Decatur, GA).
6.2.2 Primary monocyte isolation
Heparinized venous blood from female patients with benign and malignant breast
tumors was diluted 1:1 in sterile PBS and layered on Ficoll-Paque (GE healthcare)
and centrifuged at 400g for 30 minutes. The buffy coat layer was isolated, red blood
cells lysed, and peripheral blood mononuclear cells (PBMCs) were washed 3 times
in PBS. CD14+ and CD16+ monocytes were isolated using Pan-monocyte magnetic
bead isolation kit (Milteny) and lysates were collected for Bioplex kinase assay and
multiplex cathepsin zymography
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6.2.3 Multiplex cathepsin zymography
Cell extracts from monocytes and cell extracts and conditioned media from macrophages
were collected. Non-cancerous breast tissues were homogenized using homogenizer
and sonicator and lysates were collected and cleared by centrifugation. To prepare
conditioned media, differentiation media was replaced with serum-free media on day
14 and incubated overnight. Conditioned media was collected and concentrated us-
ing VivaSpinr500 Centrifugal Concentrator (Vivaproducts). Cellular protein was
extracted in lysis buffer (20 nM Tris-HCl at pH 7.5, 5 mM EGTA, 150 mM NaCl,
20 mM β-glycerol-phosphate, 10 mM NaF, 1 mM sodium orthovanadate, 1% Triton
X-100, 0.1% Tween-20) with 0.1 mM leupeptin freshly added. Cathepsin zymography
was performed on cell extracts and on conditioned media as described previously.[202]
Briefly, equal amounts of protein in non-reducing loading buffer were separated on
12.5% SDS-polyacrylamide gels containing 0.2% gelatin at 4 ◦C. Enzymes were rena-
tured and then the gels were incubated overnight at 37 ◦C in phosphate buffer, pH 6
with 1 mM EDTA and freshly added 2mM DTT. Gels were then rinsed, stained with
Coomassie blue, and imaged using an ImageQuant LAS 4000 (GE Healthcare). Den-
sitometry was performed using ImageJ to quantify the intensity of the white cleared
band of proteolytic activity.
6.2.4 Detection of CD68
To measure tissue expression level of CD68, non-cancerous breast tissue lysates were
loaded for Western blotting. Anti-CD68 antibody (Biolegend, 1:500 dilution) was
used. Signals were detected using LI-COR Odyssey.
6.2.5 Kinase phosphorylation analysis
Freshly isolated monocytes were lysed and total protein was determined using BCA
kit (Pierce). Bioplexr bead kits (BioRad) were used according to manufacturers
instructions with 5 µg protein from each sample and measured phosphorylation of
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ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), Akt (Ser473), p38 MAPK (Thr180/Tyr182),
JNK (Thr183/Tyr185), c-jun (Ser63), NFκB p65 (Ser536) and IκB-α (Ser32/Ser36). Sig-
nal values for each phosphorylated kinase were normalized to the signal detected in
a master lysate prepared in bulk from pre-stimulated cells that was used as a control
for all assays. Signal values for each kinase were normalized to maximum values for
each kinase.
6.3 Results
6.3.1 Interpatient variability in kinase activation signatures and cathep-
sin activity of circulating monocytes from breast cancer patients
To test the hypothesis that disease conditions do not obliterate patient variability
in kinase signatures and proteolytic activity of monocytes, we isolated circulating
PBMCs from female patients diagnosed with various stages of breast cancer. Whole
PBMCs or monocytes were isolated using magnetic activated cell sorting (MACS)
(Milteny) and lysed for cathepsin zymography and Bioplex kinase assays. (Figure
21A, B) For the first patient cohort, individual active cathepsins were quantified sep-
arately (35 kDa, 25 kDa and 20 kDa). For the second cohort, the amount of total
active cathepsins was quantified (Figure 21C, D). There is clear patient-to-patient
variability in monocyte cathepsin activity within the patient population. In partic-
ular, zymographic analysis of patient 4 shows uniquely high amounts of cathepsin
activity at 37kDa band, which we have identified to be cathepsin K. As we have seen
in healthy donor populations, there are patients who has JNKlowmonocytes (P1, 6
and 7), which may have higher cathepsin activity and invasion potential upon differ-
entiating into macrophages.
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Figure 21: Interpatient variability in monocyte cathepsin activity and ki-
nase activation signatures among patients with breast cancer. Circulating
PBMCs were isolated from female patients diagnosed with various stages of breast
cancer. Whole PBMCs or monocytes were isolated using magnetic beads isolation
and lysed for cathepsin zymography and Bioplex kinase assays. (A,B) Zymograph
and phosphorylated kinase measurements from a first cohort of patients are shown.
Active among of individual cathepsins (35 kDa, 25 kDa and 20 kDa) are quanti-
fied separately. (C,D) Zymograph and phosphorylated kinase measurements from
the second cohort of patients are shown. The amount of total active cathepsins was
quantified.
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6.3.2 Interpatient variability in cathepsin activity and number of macrophages
in non-cancerous breast tissues from female patients with breast
cancer
Next we tested the hypothesis that when the circulating monocytes enter tissues,
whether in healthy or disease states, the patient-specific proteolytic profile of monocyte-
derived macrophages is maintained. Non-cancerous breast tissues from the first co-
hort were obtained following mastectomy. Then the tissues were homogenized, lysates
were collected and loaded for multiplex cathepsin zymography and Western blotting
to detect macrophage CD68 expression levels. Patient 2 whose monocytes had the
greatest cathepsin activity had the lowest cathepsin activity from breast tissue lysates
(Figure 22A). Patient 1 with undetectable monocyte cathepsin activity was shown to
have highest cathepsin activity and macrophage concentration in the tissue. (Figure
22B)
6.4 Discussion
In this study, we have shown that disease conditions do not eliminate patient-to-
patient variability in monocyte kinase activation or cathepsin activity. There were
also patients whose monocytes had low level of JNK activation, which in healthy
cohort was shown to have greater cathepsin activity and invasion potential when
differentiated into macrophages (Figure 16). Also JNK inhibition most effectively re-
duced macrophage cathepsin activity and cancer cell invasion for these healthy donors
as well (Figures 13 and 14). Although it still remains to be investigated whether indi-
vidual patients pre-disease monocyte kinase signature and cathepsin activity profile is
conserved through development and progression of breast cancer, findings from these
patients introduces the exciting possibility of reducing invasiveness for patients with
the most aggressive tumors. Furthermore, monocyte kinase and cathepsin profiling
would serve as a minimally invasive method to perform at patients initial visit that
can inform chemotherapy regimens, as well as invasive potential of non-malignant
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Figure 22: Interpatient variability in cathepsin activity and number of
macrophages in non-cancerous breast tissues from female patients with
breast cancer After patients underwent mastectomy, non-cancerous part of breast
tissue was collected, homogenized and loaded for multiplex cathepsin zymography
to measure the amount of active cathepsins (A) and Western blotting to quantify
expression of macrophage marker CD68 (B).
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DCIS, which has the highest incidence of overdiganosis.
It has long been suggested that chronic inflammatory states can lead to develop-
ment of cancer.[6] Tumor microenvironment is comprised of myriad of immune cells
and immune modulators that supports or fights cancer development.[28, 66, 173] Fur-
thermore, recent studies have identified circulating factors or circulating tumor cells
that is upregulated at different stages of cancer and can be used as a biomarker.[30]
All these cues could potentially interact with circulating monocytes and the mono-
cytes that enter tumor tissue and can affect their phenotype and proteolytic activity.
Taken together, it remains to be investigated whether disease state leads to a distinct
shift in kinase signatures and if so, whether the distinct individual kinase signature
is still maintained despite this shift.
The results from the previous chapter suggested that individual donors could have
intrinsically different M1/M2 macrophage ratio and that macrophage subtypes may
have distinct cathepsin activity profile. In some cancers, M2 macrophages, or tumor-
associated macrophages have been shown to promote tumor progression and are as-
sociated with poor prognosis.[95, 130] Distinct cytokines that are present in tumor
microenvironment drives macrophage polarization. Therefore it should be investi-
gated whether monocyte kinase signatures and cathepsin activity profile is maintained
once they differentiate into macrophages in breast tissues, both in healthy conditions
and within tumor tissues as well as whether there is predictable correlation between
them. In addition, it is also unknown whether this intrinsic macrophage subtype
ratio is maintained in tumor microenvironment and whether they are predictive of
disease trajectory, and whether different stages of breast cancer have distinguishing
monocyte kinase signature and proteolytic profile.
This study also provides a basis for in vivo studies to determine the efficacy
of targeted inhibition of JNK activation in monocytes with the long-term goal of
reducing invasion of the most invasive tumors. As JNK inhibition has been shown
74
to decrease breast cancer cell proliferation and promote apoptosis,[137] there may be
a synergistic benefit in targeting the pathway. Through patient-specific analysis of
monocyte kinase signature and cathepsin activity, it maybe possible to identify the




As a whole, this work was aimed to address the issues of patient variability in disease
contributing phenotypes by monocyte-derived cells with special emphasis on cysteine
cathepsin which mediated tissue destructive diseases namely, breast cancer. Many
studies have investigated patient variability at the genomic level, with the goal of
achieving personalized predictive medicine. These studies revealed helpful insights,
but there are many regulatory steps between information coded in genes down to
where cells are executing various functions with number of factors such as cytokines,
kinases and proteases. The main contribution of the current work to the field of
personalized medicine is showing that patient-variability in disease progression can
be influenced by variability in cellular proteolytic activity, which can be predicted by
multivariate analysis of set of kinases. As discussed previously, there are bevy of cir-
culating factors, such as cytokines and hormones that modulates monocyte behavior
but cannot be measured explicitly. However, by using a systems biology approach to
link cell differentiation cues and responses through the integration of signals at the
kinase level, where integration of ubiquitous information is processed intelligently by
the differentiating cell, we were able to mathematically predict relative amounts of
cathepsin activity and distinguish the donors with higher cathepsin activity. Impli-
cation of this finding in furthering personalized medicine is that with the analysis of
kinase signatures of monocytes isolated through a simple blood draw from individ-
uals, patient-specific disease potential could be predicted without extensive profiling
of cytokines and other circulating factors.
Cathepsin activity has been mechanistically linked to malignant transformation,
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angiogenesis, tumor invasion, growth, metastasis in context of tumor,[138, 55, 81,
207, 178, 21, 90, 203, 62, 197, 172, 143, 110, 57, 200] to transmigration of monocytes,
macrophage lipid metabolism, elastic lamina degradation and plaque rupture in the
context of atherosclerosis.[157, 158, 156, 185, 117, 26] Because of this, tissue levels
of cathepsins are not just surrogates, but functional biomarkers whose level could
be directly correlated to disease progression and inform treatment strategy. Cathep-
sin B, in particular, perhaps due to its abundance in cells, has been investigated as
biomarker for cancer over 30 years.[176] Cysteine cathepsins K, L, S, V and X have
been investigated as well with mixed success.[10, 46] However, it has been difficult to
reliably measure the amount of individual active cathepsins, as cathepsins are very
closely related structurally. In addition, the ubiquitous presence of the endogenous
inhibitors, cystatins and stefins can interfere with accurate measurement of active
cathepsins. There is also a lack of a consensus to report cathepsin gene expression,
pre-, mature-, or total cathepsin protein level or activity level as biomarkers. The
later obstacle could be attributed to substrate cross reactivity and closely related
enzyme structure. Much effort has also been made to inhibit cathepsin activities for
therapeutic values.[154, 193, 151, 198] The most heavily targeted cysteine cathepsin
is cathepsin K for its role in bone resorption that occurs during osteoporosis and bone
metastasis.[99, 18] However, only the cathepsin K inhibitor, odanacatib successfully
completed phase III clinical trial.[182] Most clinical trials were halted due to side ef-
fects or lack of therapeutic efficacy. Both biomarker studies and drug trials investigate
the patient cohort as a one large unit instead of examining individual differences. This
approach is necessary of course to elucidate disease-specific mechanisms, biomarkers
or treatment efficacy with statistical power. However, interpatient variability can
reduce statistical power and can negate patient-specific effects. For example, it was
shown in the current study that on a population level, there seemed to be no sig-
nificant effect on cystatin C level and cancer cell invasion upon inhibiting JNK in
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differentiating monocytes. However, when examined closely at the individual patient
level, there were patients who indeed responded to the inhibition with decrease or
increase in these outcomes. Although identifying patient-specific biomarkers and re-
sponses to therapy can be time consuming and cost-prohibitive, personalized approach
is becoming much more feasible and potentially more efficient and effective with the
rapid advancement in computational biology and omic-scale analysis,[147, 54, 195]
This work suggests that in addition to genomic and metabolomics analysis, person-
alized medicine could benefit from systems-scale analysis of kinases and proteolytic
networks.
Furthermore, studies have shown that macrophages and cathepsins can blunt the
effect of chemotherapeutic agents.[172, 32, 5] Although, there are many tumor-specific
and patient-specific factors that confers resistance to chemotherapies,[35, 210] results
from this study suggest a potential new mechanism of resistance for certain patients.
Specifically, patients with higher macrophage cathepsin activity may have greater
potential for developing resistance. However, the finding that among these patients,
JNK inhibition effectively reduces macrophage cathepsin activity can be used to im-
prove treatment efficacy of main chemotherapeutics through reduced resistance.
Results from this work also suggested donor-to-donor variability in the makeup
of polarized macrophage subtypes. Although traditionally, macrophage polarization
was known to be a dichotomy, now studies have shown there is a continuous spectrum
of macrophage phenotypes and they can switch between the subtypes based on envi-
ronmental cues.[174, 140] For example, in atheroma, a heterogeneous population of
macrophage subtypes are found, where the M1-phenotype promotes inflammation and
atherogenesis and M2-phenotype is atheroprotective.[123] In the current work, when
donor monocytes were stimulated with a single cue, M-CSF, resultant macrophage
population displayed mixed M1 and M2 phenotypic markers. We can hypothesize
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that patient-specific circulating cues have primed monocytes prior to isolation, driv-
ing preferential polarization. These phenomena may lead to a greater propensity for
inflammatory diseases or provide greater protection against them. Further investi-
gation on this interpatient variability could reveal additional predictive metric for
patient-specific disease potential.
Disease state introduces an altered or new set of cues that can modulate prote-
olytic behavior of circulating monocytes and differentiating macrophages that have
entered tumor tissue or developing plaques. Questions have been raised whether dis-
ease conditions equalize or reduce patient-to-patient variability by preconditioning
circulating cells with similar disease-specific cues. Results from this work suggest
that the patient-variability is maintained. Further work with a larger patient co-
hort along with the comparison to a healthy population will be able to more clearly
elucidate the effect of disease state on patient-variability. However, we were able
to identify patients with monocytes with low JNK activation. In the healthy popu-
lation, monocytes from these individuals when differentiated into macrophages had
high cathepsin activity and invasive potential, which were significantly reduced upon
JNK inhibition. Therefore it is promising that these metrics can be used to identify
breast cancer patients who may be develop more aggressive cancer and can benefit
from targeted JNK inhibition.
Findings from the current study could be applied to other tissue-destructive
diseases mediated by cathepsins and monocyte-derived cells such as macrophages.
Atherosclerosis is another tissue remodeling diseases where cathepsins and macrophages
have been shown to play key roles in disease development and progression.[31, 88,
115, 114, 116, 185, 184, 24, 186, 117] The earliest changes that leads to atheroscle-
rosis occurs in endothelial layers at sites of low, and oscillatory shear stress such
as arches and bifurcations. Cathepsin expression and activity is regulated by shear
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stress and low and oscillatory shear stress have been shown to upregulate expres-
sion and activity of cathepsins K and L by endothelial cells.[157, 158, 156] Cathepsin
S was shown to aid macrophage transmigration through endothelial monolayer in
vitro.[185] Cathepsins also play roles in lipid metabolism, which furthers atheroscle-
rotic plaque formation.[117] In turn, increased levels of oxidized LDL, which leads to
foam cell formation, was shown to disrupt lysosomal membrane, leading to reloca-
tion of cathepsins B and L to cytoplasm.[26] As atherosclerosis progresses, cathepsins
secreted by macrophages degrade elastic lamina and facilitate migration of smooth
muscle cells, which produces collagen as well as cathepsin K, into neointimal space.
Higher plaque collagen content is correlated with increased plaque stability. Further-
more, the pathophysiological importance of cathepsins in atherosclerosis has been
demonstrated in double-knockout mice deficient in apolipoprotein E (ApoE) and
cathepsins K, S or L, which showed a reduction in the number and size of atheroscle-
rotic lesions, decreased fragmentation of the elastic lamina, and decreased plaque
rupture.[116, 184, 164, 88] Double-knockout mice deficient in ApoE and Cystatin C
experienced an increase in atherosclerosis.[9] Even osteoclasts have been implicated in
later stages of atherosclerotic plaque calcification and shown to be differentiated from
infiltrated monocytes.[2, 1, 133] Therefore, findings from this study has an implica-
tion that those individuals with greater cellular cathepsin activities may have greater
propensity of developing atherosclerotic plaques or greater risk of plaque rupture and
merits further investigation for personalized medicine strategies.
Patient-to-patient variability seen in these diseases has been an added challenge
for physicians to properly diagnose and treat their patients. This work demonstrates
that interpatient variability at the level of cellular protease activity and other disease-
mediating phenotypes must be examined in addition to genomic analysis. Incorporat-
ing this knowledge for patient-specific diagnosis and treatment can bring physicians




Cathepsins have long been investigated as biomarkers and therapeutic targets in can-
cer and cardiovascular diseases. Patient-to-patient variability seen in these diseases
has been an added challenge for physicians to properly diagnose and treat their pa-
tients. This work illustrates the importance of investigating interpatient variability
not only at the genomic level, but also at the level of cellular protease activity and
other phenotypes that mediate disease progression. Incorporating this knowledge for
patient-specific diagnosis and treatment can bring physicians one-step closer to the
ultimate goal of personalized medicine.
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M. A., Overkleeft, H. S., Kraaijeveld, A. O., Dorland, R., van
Santbrink, P. J., van Heiningen, S. H., Westra, M. M., Kovanen,
P. T., Jukema, J. W., van der Wall, E. E., van Berkel, T. J. C., Shi,
G. P., and Biessen, E. A. L., “Leukocyte cathepsin S is a potent regulator
of both cell and matrix turnover in advanced atherosclerosis.,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 29, pp. 188–194, Feb. 2009.
[32] De Palma, M. and Lewis, C. E., “Macrophage regulation of tumor responses
to anticancer therapies.,” Cancer Cell, vol. 23, pp. 277–286, Mar. 2013.
84
[33] De Tommasi, E., Rea, I., and Rendina, I., “Unlicensed electronic item,”
SPIE . . . , 2011.
[34] DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao,
S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D.,
Junaid, S. A., Rugo, H. S., Hwang, E. S., Jirström, K., West, B. L.,
and Coussens, L. M., “Leukocyte complexity predicts breast cancer survival
and functionally regulates response to chemotherapy.,” Cancer discovery, vol. 1,
pp. 54–67, June 2011.
[35] Denisov, E. V., Litviakov, N. V., Zavyalova, M. V., Perelmuter,
V. M., Vtorushin, S. V., Tsyganov, M. M., Gerashchenko, T. S.,
Garbukov, E. Y., Slonimskaya, E. M., and Cherdyntseva, N. V.,
“Intratumoral morphological heterogeneity of breast cancer: neoadjuvant
chemotherapy efficiency and multidrug resistance gene expression.,” Scientific
reports, vol. 4, p. 4709, 2014.
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as treatment of bone metastasis.,” Current opinion in supportive and palliative
care, vol. 2, pp. 218–222, Sept. 2008.
[100] Lee, A. H., Happerfield, L. C., Bobrow, L. G., and Millis, R. R.,
“Angiogenesis and inflammation in invasive carcinoma of the breast.,” Journal
of clinical pathology, vol. 50, pp. 669–673, Aug. 1997.
[101] Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T., “Activation of
the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway.,”
Cell, vol. 88, pp. 213–222, Jan. 1997.
[102] Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J.,
and Harris, A. L., “Association of macrophage infiltration with angiogenesis
and prognosis in invasive breast carcinoma.,” Cancer research, vol. 56, pp. 4625–
4629, Oct. 1996.
92
[103] Lewis, C. E., “Distinct Role of Macrophages in Different Tumor Microenvi-
ronments,” Cancer research, vol. 66, pp. 605–612, Jan. 2006.
[104] Lewis, J. S., Landers, R. J., Underwood, J. C., Harris, A. L.,
and Lewis, C. E., “Expression of vascular endothelial growth factor by
macrophages is up-regulated in poorly vascularized areas of breast carcinomas.,”
The Journal of Pathology, vol. 192, pp. 150–158, Oct. 2000.
[105] Li, W. A., Barry, Z. T., Cohen, J. D., Wilder, C. L., Deeds, R. J.,
Keegan, P. M., and Platt, M. O., “Detection of femtomole quantities
of mature cathepsin K with zymography,” Analytical Biochemistry, vol. 401,
pp. 91–98, June 2010.
[106] Li, Z., Hou, W.-S., Escalante-Torres, C. R., Gelb, B. D., and
Brömme, D., “Collagenase activity of cathepsin K depends on complex for-
mation with chondroitin sulfate.,” The Journal of biological chemistry, vol. 277,
pp. 28669–28676, Aug. 2002.
[107] Li, Z., Kienetz, M., Cherney, M. M., James, M. N. G., and Brömme,
D., “The crystal and molecular structures of a cathepsin K:chondroitin sulfate
complex.,” Journal of Molecular Biology, vol. 383, pp. 78–91, Oct. 2008.
[108] Li, Z., Yasuda, Y., Li, W., Bogyo, M., Katz, N., Gordon, R. E.,
Fields, G. B., and Brömme, D., “Regulation of collagenase activities of
human cathepsins by glycosaminoglycans.,” The Journal of biological chemistry,
vol. 279, pp. 5470–5479, Feb. 2004.
[109] Lin, E. Y., Nguyen, A. V., Russell, R. G., and Pollard, J. W.,
“Colony-stimulating factor 1 promotes progression of mammary tumors to ma-
lignancy.,” The Journal of experimental medicine, vol. 193, pp. 727–740, Mar.
2001.
[110] Lindahl, C., Simonsson, M., Bergh, A., Thysell, E., Antti, H., Sund,
M., and Wikström, P., “Increased levels of macrophage-secreted cathepsin
S during prostate cancer progression in TRAMP mice and patients.,” Cancer
genomics & proteomics, vol. 6, pp. 149–159, May 2009.
[111] Liotta, L. A., Kohn, E. C., and Petricoin, E. F., “Clinical proteomics:
personalized molecular medicine.,” JAMA: The Journal of the American Med-
ical Association, vol. 286, pp. 2211–2214, Nov. 2001.
[112] Littlewood-Evans, A. J., Bilbe, G., Bowler, W. B., Farley, D.,
Wlodarski, B., Kokubo, T., Inaoka, T., Sloane, J., Evans, D. B.,
and Gallagher, J. A., “The osteoclast-associated protease cathepsin K is
expressed in human breast carcinoma.,” Cancer research, vol. 57, pp. 5386–
5390, Dec. 1997.
93
[113] Liu, J., Ma, L., Yang, J., Ren, A., Sun, Z., Yan, G., Sun, J., Fu, H.,
Xu, W., Hu, C., and Shi, G.-P., “Increased serum cathepsin S in patients
with atherosclerosis and diabetes.,” Atherosclerosis, vol. 186, pp. 411–419, June
2006.
[114] Liu, J., Sukhova, G. K., Sun, J.-S., Xu, W.-H., Libby, P., and Shi, G.-
P., “Lysosomal cysteine proteases in atherosclerosis.,” Arteriosclerosis, Throm-
bosis, and Vascular Biology, vol. 24, pp. 1359–1366, Aug. 2004.
[115] Liu, J., Sukhova, G. K., Yang, J.-T., Sun, J., Ma, L., Ren, A., Xu,
W.-H., Fu, H., Dolganov, G. M., Hu, C., Libby, P., and Shi, G.-P.,
“Cathepsin L expression and regulation in human abdominal aortic aneurysm,
atherosclerosis, and vascular cells.,” Atherosclerosis, vol. 184, pp. 302–311, Feb.
2006.
[116] Lutgens, E., Lutgens, S. P. M., Faber, B. C. G., Heeneman, S., Gij-
bels, M. M. J., de Winther, M. P. J., Frederik, P., van der Made,
I., Daugherty, A., Sijbers, A. M., Fisher, A., Long, C. J., Saftig,
P., Black, D., Daemen, M. J. A. P., and Cleutjens, K. B. J. M., “Dis-
ruption of the cathepsin K gene reduces atherosclerosis progression and induces
plaque fibrosis but accelerates macrophage foam cell formation.,” Circulation,
vol. 113, pp. 98–107, Jan. 2006.
[117] Lutgens, S. P. M., Cleutjens, K. B. J. M., Daemen, M. J. A. P., and
Heeneman, S., “Cathepsin cysteine proteases in cardiovascular disease.,” The
FASEB Journal, vol. 21, pp. 3029–3041, Oct. 2007.
[118] Maciewicz, R. A. and Etherington, D. J., “A comparison of four cathep-
sins (B, L, N and S) with collagenolytic activity from rabbit spleen.,” The
Biochemical journal, vol. 256, pp. 433–440, Dec. 1988.
[119] Mai, J., Sameni, M., Mikkelsen, T., and Sloane, B. F., “Degradation of
extracellular matrix protein tenascin-C by cathepsin B: an interaction involved
in the progression of gliomas.,” Biological chemistry, vol. 383, pp. 1407–1413,
Sept. 2002.
[120] Mantovani, A., “B cells and macrophages in cancer: yin and yang,” Nature
Publishing Group, vol. 17, pp. 285–286, Mar. 2011.
[121] Mantovani, A., Allavena, P., Sica, A., and Balkwill, F., “Cancer-
related inflammation.,” Nature, vol. 454, pp. 436–444, July 2008.
[122] Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., and Locati,
M., “Macrophage plasticity and polarization in tissue repair and remodelling.,”
The Journal of Pathology, Oct. 2012.
[123] Mantovani, A., Garlanda, C., and Locati, M., “Macrophage diversity
and polarization in atherosclerosis: a question of balance.,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 29, pp. 1419–1423, Oct. 2009.
94
[124] Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., and
Locati, M., “The chemokine system in diverse forms of macrophage activation
and polarization.,” Trends in immunology, vol. 25, pp. 677–686, Dec. 2004.
[125] Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica,
A., “Macrophage polarization: tumor-associated macrophages as a paradigm
for polarized M2 mononuclear phagocytes.,” Trends in immunology, vol. 23,
pp. 549–555, Nov. 2002.
[126] Mart́ın-Fuentes, P., Civeira, F., Recalde, D., Garćıa-Ot́ın, A. L.,
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